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Melanie Victoria Brady 
2021 
 
Ventral telencephalic development gives rise to the basal ganglia, a subpallial brain 
region responsible for motor function and coordination. This brain region is implicated in 
many movement disorders, including Tourette Syndrome (TS). TS is a heterogenous 
neurodevelopmental disorder and its etiopathophysiology is unknown. To date, TS has 
been investigated in animal models and postnatal human subjects, but early 
development of this disorder has not been studied. Previous work in adult TS post 
mortem basal ganglia tissue has shown a reduction in striatal interneurons, which serve 
to largely regulate striatal output. However, possible mechanisms for this neuronal loss 
and whether or not these findings originate in early development are poorly understood. 
 
This study examines TS etiology by modeling basal ganglia development in 
tridimensional human induced pluripotent stem cell-derived neural organoids. Basal 
ganglia organoids were generated from and compared across healthy unaffected 
control individuals and adult unremitting TS patients. We found early telencephalic 
patterning disruptions in TS-derived basal ganglia organoids, showing a preference for 
dorsal-posterior specification instead of the expected ventral-anterior commitment seen 
in healthy control-derived organoids. The aberrant fate shift in the TS-derived basal 
 ii 
ganglia organoids was seen at both RNA and protein levels, confirmed across three 
separate assays, with consistency across three distinct time points. Transcriptome 
analyses in the organoids further identified categories of neuronal deficits that show 
overlap with a manually curated list of differentially expressed genes uncovered by 
transcriptome analyses at the post mortem level, reiterating the relevance of the 
bioassay utilized in this study. 
 
This work also investigated a potential mechanism for the early developmental 
phenotypes observed in the TS organoids. We found significant alterations in sonic 
hedgehog (SHH) signaling components at both RNA and protein levels that are 
essential for distinguishing dorsal-ventral patterning in the human brain. Additionally, 
transcriptome analyses reveal a potential role for cilia, the cellular protrusions that 
facilitate SHH signal transduction. We found disruptions in genes that are required for 
cilia formation and function in the TS basal ganglia organoids that were absent from the 
healthy controls. 
 
This study leads an early developmental examination of TS in humans and offers a 
bioassay applicable to modeling basal ganglia-related disorders. These results reveal 
new biomarkers of interest in TS etiology and describe a new implication for SHH 
signaling. These results indicate that TS patients may exhibit altered telencephalic 
development, which yields deficits in neurons that ultimately populate the basal ganglia 
and regulate optimal circuitry function. 
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During embryonic development, the ventral telencephalon gives rise to the three 
ganglionic eminences – medial, lateral and caudal; these regions generate various 
classes of interneurons that eventually migrate to the cortex and olfactory bulb, and 
even the amygdala and hippocampus, essentially populating the forebrain [1-3]. The 
transcriptional signature of the ventral telencephalon is first initiated and controlled by 
the sonic hedgehog (SHH)-secreting notochord, which in turn specifies the medial 
ganglionic eminence and other ventral regions. This ventral specification is pioneered 
by the direct activation of the transcription factor NKX2.1, fostering a transcriptional 
program that is distinct from that of the dorsal telencephalon [4]. These dorsal-ventral 
axes detail a region-specific topography of the forebrain that houses specific cellular 
lineages. As an early determinant of ventral telencephalic fate, NKX2.1, in direct 
response to SHH signaling, antagonizes dorsal gene expression in this ventral 
region[5]. The ventral telencephalon ultimately develops into the basal ganglia, and this 
region’s functional circuitry is critical for movement and motor coordination. 
 
Basal ganglia circuitry dysfunction is implicated in several movement disorders, a 
common one being Tourette Syndrome (TS), which is characterized by motor and vocal 
tics [6]. However, current approaches in the field to advance our understanding of TS 
often have several limitations. First, classified as a neurodevelopmental disorder, TS is 
postulated to manifest early in development; however, most human-based strategies 
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investigate adult individuals, or examine adult post mortem brain tissue. For instance, 
neuroimaging evidence suggests a decrease in striatal volume in TS patients [7], and 
our lab has previously shown a significant decrease in several classes of inhibitory 
GABAergic interneurons in post mortem basal ganglia tissue of adult TS patients [8-10]. 
While these approaches yield critical information to aid in our understanding of this 
complex and heterogeneous disorder, the optimal developmental period fails to be 
captured, and therefore these studies leave several questions to be addressed when 
ascertaining disorder etiology. Second, alternative model systems for studying TS 
include rodents and non-human primates, each with their own limitations. In these 
organisms, the animals are genetically modified to artificially present with 
neurobiological and behavioral symptoms aimed to mimic the human phenotypes. In 
these synthetic approaches, however, disrupting the natural development of these 
organisms to force a disorder that these subjects would otherwise not experience can 
yield unintended results; further, deciphering and decoding the non-human behavioral 
findings in an attempt to match a human disorder is challenging and often yields unclear 
results and conclusions, as well. Third, the aforementioned complexities arise from the 
ethical fact that we do not have access to human brain tissue from early developmental 
time points. Therefore, in order to model TS, an early developmental human system is 
necessary.  
 
Tridimensional (3D) human induced pluripotent stem cell (iPSC)-derived neural 
organoids have emerged as a versatile in vitro model with vast therapeutic potential due 
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to the system’s capability to mimic early aspects of human brain development [11-13]. 
This system is optimal for the investigation of human cellular fates and brain region-
specific commitments at the genomic, transcriptomic, molecular and cellular level that 
cannot be achieved with current rodent models or human patients. However, most 
organoid strategies give rise to neuronal cells mainly comprised of cortical excitatory 
lineages, resulting from a dorsal telencephalic commitment [11-13].  
 
The goal of this thesis is to investigate the development of basal ganglia organoids 
across TS patients and healthy control individuals to identify the underlying 
neurobiology and mechanisms of disorder active during neurodevelopment in order to 
contribute to the field’s understanding of the disease’s etiopathophysiology. First, a new 
iPSC-derived 3D organoid strategy to recapitulate human basal ganglia development at 
the embryonic and fetal stages is developed. Next, the novel in vitro approach is utilized 
in a series of experiments to explore differences in neurodevelopment at both RNA and 
protein levels across TS patients and control subjects. Finally, further investigations at 
the RNA and protein level guide the identification of a developmental mechanism that 
explains the in vitro phenotype observed. This work establishes a versatile model 
system to facilitate the study of the wide range of neurodegenerative diseases and 
neurodevelopmental disorders perturbing the basal ganglia. Further, this research 
elucidates potential biomarkers of TS to provide possible avenues for therapeutic 
advancement and improvement of clinical assessment of the disorder. 
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Aim I: Develop a protocol to generate organoids that resemble the basal ganglia, resulting 
from a ventral telencephalic commitment. 
Most current organoid strategies give rise to dorsal telencephalic cortical fates [11-15]. 
Additionally, the current few that give rise to ventral telencephalic fates [16, 17] do not 
generate the broad range of neuronal types that are essential components of the basal 
ganglia and, more specifically, cholinergic interneuron populations. As evidenced from 
previous findings, cholinergic expression is of particular interest for investigating cellular 
and molecular abnormalities linked to TS [8-10], making these existing protocols 
suboptimal for the goals stated here. We previously developed a cortical organoid model 
to examine pathogenesis of ASD [13, 18], and I have since employed modifications to 
enrich for a basal ganglia-like cellular commitment within the organoids. In this aim, and 
detailed in Chapter 4 of this thesis, I have carefully optimized the type, concentration and 
timing of a novel cocktail of ventral morphogens, such as fibroblast growth factor (FGFs), 
in order to culture 3D organoids that favor ventral basal ganglia development over dorsal 
cortical or caudal hindbrain. Extensive analysis of data obtained via three separate 
assays – immunocytochemistry and stereological counts, real-time qPCR, and bulk RNA 
sequencing – reveals the emergence of ventral telencephalic transcriptional patterning 
within the basal ganglia organoids, with a preference towards medial and lateral 
ganglionic eminence development. Additionally, these basal ganglia organoids show a 
variety of ventral progenitors as well as the maturation of ventral telencephalon-
originating GABAergic neurons for the striatum and cerebral cortex. Further, two-photon 
imaging of late-stage organoids show robust and extended maturation up to a year in 
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culture, as well as the development of putative synaptic spines, suggesting functionality 
of the system. The analyses provided here suggest the achievement of a model for human 
embryonic/fetal ventral telencephalon, fostering the neuronal diversity integral to the 
human cortico-basal ganglia network. This model is applied to investigate TS, in which 
this delicate cellular milieu is perturbed. 
 
Aim II: Generate basal ganglia organoids from TS patients and unaffected healthy control 
individuals, and determine the possible developmental underpinnings of morphological, 
cellular and transcriptional differences found in adulthood. 
The iPSC lines were generated from five (n=5) adult individuals with severe, unremitting 
TS. Basal ganglia organoid cultures were differentiated from both TS probands and 
unaffected healthy control (CT, n=10) individuals using two separate clonal lines per 
subject. In this aim, and detailed in Chapter 5 of this thesis, I compare the ability of the 
CT and TS iPSC lines to differentiate into ventral telencephalic progenitors and post-
mitotic GABAergic and cholinergic neurons by using the protocol designed in Aim I. Using 
immunocytochemistry, real-time qPCR and bulk RNA sequencing, a developmental 
deficit is revealed whereby TS-derived basal ganglia organoids are mispatterned at both 
RNA and protein levels and across three time points. Furthermore, the findings reveal 
alterations in the expression of synaptic molecules that intensify over time in the TS-
derived basal ganglia organoids, suggesting potential functional disruptions. The 
transcriptome  results from the TS-derived basal ganglia organoids were compared to the 
previously published transcriptome data from adult TS post mortem brain tissue to find 
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considerable overlap in differential gene expression between patients and controls. 
Together, these data identify a developmental deficit in TS-derived organoids that can 
help elucidate the human phenotype clinically observed. 
 
Aim III: Identify a developmental mechanism for the observed mispatterning of the ventral 
telencephalon in TS-derived basal ganglia organoids. 
Given the developmental deficits observed under Aim II (as detailed in Chapter 5 of this 
thesis), I attempted to investigate the earlier molecular occurrences within the organoids 
that could bring further understanding to the findings. In this aim, and detailed in Chapter 
6 of this thesis, I target the SHH pathway to uncover differences across the TS and CT 
basal ganglia organoids that provide an explanation for the phenotype observed in the 
TS samples. To achieve this, I focus on the earliest time point at which basal ganglia 
patterning occurs within the organoids, with a shift towards a ventral telencephalic 
commitment, to identify potential reasons for the TS phenotype observed across time. 
The data are obtained at both RNA and protein levels utilizing three separate assays to 
explore these alterations. The results indicate disruptions in the SHH signaling pathway, 
with enhanced expression of proteins that are typically exclusive to the dorsal 
telencephalon in TS organoids as compared to controls. 
 
Background and Significance 
TS is a chronic neurodevelopmental disorder manifesting in childhood and affecting 
roughly 0.6% of children [19]. Repetitive motor and vocal tics, such as eye-blinking or 
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throat clearing, are the defining symptomatology of the disorder [20]. Approximately 
one-fourth of the children diagnosed with TS present with tics that continue into 
adulthood. Across patients, adults largely experience the most severe, refractory and 
incapacitating cases of tics [6]. The behavioral characteristics of the disorder suggest a 
complex integration of diverse sensory, motor and cognitive functions yielding TS onset. 
While there have been substantial empirical efforts by international associations 
contributing to the examination of more than 1400 TS and 5200 control (CT) blood 
samples, a limited number of risk genes have been discovered according to genome-
wide statistical thresholds [21-24]. Further, no causative or predisposing biomarkers 
have been identified. Although analyses of rare family-specific copy number variants 
and genomic variants implicate a few genomic loci in TS, these remain unfitting as 
potential causes for commonly occurring TS, the majority of which remain unknown [25-
29]. 
 
Dysregulation of basal ganglia circuitry is a primary hypothesis to describe TS 
pathophysiology. The basal ganglia reside beneath the cortex, comprised of the 
striatum, globus pallidus internal and external segments, substantia nigra and 
subthalamic nucleus. Functional circuitry emerging from these nuclei are critical for 
proper execution of coordinated motor behavior, and initiation and maintenance of 
efficiently patterned motor programming [30]. The basal ganglia receive glutamatergic 
cortical and thalamic projections innervating the striatum. Cortical input ultimately drives 
GABAergic medium spiny neuron (MSN) activity, regulated by different basal ganglia 
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interneuron populations. Basal ganglia output to the thalamus is regulated by two major 
striatum-originating anatomical pathways: the direct and indirect pathways, which elicit 
opposing functional effects [30]. The direct pathway promotes voluntary motor behavior 
by relieving inhibition of thalamic neurons and facilitating excitatory feedback to the 
cortex. In an opposite manner, the indirect pathway thwarts motor behavior via inhibiting 
thalamic neuronal activity and diminishing excitatory feedback to the cortex. In TS, tic 
release elicits prominent activity in the basal ganglia, the anatomical and neuronal 
modification of which are correlated with the disorder [6, 20]. Neuroimaging data 
suggest decreases in volume of the striatum (comprising the caudate and putamen) in 
TS patients (See Chapter 1B and Figure 11.1 for a depiction of basal ganglia regions) 
[31, 32]. This is consistent with our post mortem findings of significant decreases in 
cholinergic (CH/TAN) [8, 9], parvalbumin (PV) [8, 9, 25, 26], and SST/NOS/NPY [10] 
GABAergic interneuron immunoreactivity in these basal ganglia regions, suggesting 
loss and/or dysfunction of interneurons in adult TS patients [25, 26].  
 
We hypothesize that decreases in several classes of TS patients’ striatal interneurons 
disrupt the equilibrium of functional basal ganglia pathways, encouraging tic release. 
Cortical innervation of the striatum excites the fast-spiking GABAergic PV+ interneurons 
[33-35], selectively inhibiting MSNs designated for the direct pathway [36, 37]. 
Additionally, intralaminar thalamic nuclei project to the striatum, activating the tonically 
active CH/TAN+ interneurons [38], subsequently exciting and regulating PV+ 
interneurons [39]. Conceivably then, alterations in striatal PV+ and CH/TAN+ number 
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and activity should disrupt the thalamic output regulated by direct pathway activation, 
and to that effect, both thalamic and cortical influences on direct pathway activity. 
 
An accurate basal ganglia model is critical for both basic and clinical studies, with 
implications for TS and several other neurological diseases and neurodevelopmental 
disorders. Basal ganglia dysfunction and TS have been modeled in various organisms – 
from rodents to non-human primates – but heterogeneity of the disorder limits the 
relevance of certain animal systems. For instance, rodent models generated by different 
disorder’s mutations can have the same resultant increased grooming behavior, which 
has been evaluated as a key phenotype of trichotillomania [40], Autism Spectrum 
Disorder (ASD) [41] and OCD [42], in addition to TS. The commonality of such repetitive 
behaviors greatly weakens the claim that a given behavioral abnormality is 
characteristic of a particular disorder. Additionally, with humans possessing the most 
complex neural development and circuitry, the anatomical differences across species 
impact the degree to which disease pathophysiology can be convincingly captured. 
Thus, the use of a developmental in vitro human model system, with the potential to 
differentiate into whole brain regions, is uniquely suited to address the pathophysiology 
of disease in the absence of useful models for early human development. 
 
Neural organoids are 3D multilayered aggregates capable of recapitulating human 
embryonic development. Comparison of the organoids’ transcriptome at various 
developmental stages with post mortem data found our neural organoids correlated best 
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with the dorsal telencephalon and spanning 8-16 postconceptional weeks of human 
fetal development [15, 18]. However, representation of the ventral forebrain is lacking 
from the majority of existing organoid protocols. Generating organoids that model basal 
ganglia development will facilitate investigation of TS and other neurodevelopmental 
disorders targeting this brain region. 
 
Summary 
This thesis aims to advance our understanding of TS etiology and human basal ganglia 
development. First, I aim to develop an iPSC strategy to model human basal ganglia 
development in 3D organoids – a system which will foster a clinically-relevant 
assessment of how TS arises and unfolds. Next, I am to use this technology to compare 
basal ganglia development across control and TS individuals by conducting cellular, 
molecular and transcriptome analyses and uncover new underpinnings of the disorder. 
Finally, I aim to identify a developmental mechanism for the differences in development 
that are observed. Results of these studies will be presented in Chapters 4, 5, and 6 of 
this thesis, respectively, followed by a discussion in Chapter 7 including implications of 






Tourette Syndrome & its Cellular and Molecular Pathology 
 
Chapter 1A: Tourette Syndrome 
The following review examines the phenomenology of TS, detailing the clinical 
presentations and the evolution of our empirical and medical understanding of the 
disorder. Additionally, limitations in current treatment methods are described. This 
section reveals the complexities of TS that have contributed to the challenges 
surrounding studying this disorder. Comprehensively, this section outlines the current 
and historical information necessary to understand the neuropsychiatric disorder that 
this thesis investigates. 
 
1. Summary 
1.1Disease Characteristics, Hallmark Manifestations and Inheritance  
Tourette syndrome (TS) is a childhood-onset psychiatric disorder characterized by 
chronic motor and phonic tics [43]. Symptoms typically vary in nature and frequency 
over time and, in the majority of cases, decrease with age [6, 44]. Approximately one-
third of the children diagnosed with TS present with tics that continue into adulthood. 
Across patients, adults often experience the most severe, refractory and incapacitating 
cases of tics [6]. There is strong evidence of a genetic contribution; however, candidate 
genes revealed by family studies are not significant risk genes for the majority of the 
population, and association studies have not identified common variants above 
threshold significance [22, 25, 26, 45-48]. 
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1.2 Diagnosis and testing  
TS is diagnosed when both motor and vocal tics are present for more than 12 months, 
with onset before age 18, and is estimated to occur in 0.1-1% of children [49]. As there 
are currently no physiological or genetic tests, diagnosis occurs through clinical 
evaluation [50]. 
 
1.3 Current research 
Several brain regions have been implicated in TS, primarily the caudate nucleus and 
putamen in the basal ganglia of the striatum,  but also the cerebral cortex, hippocampus 
and cerebellum [7-9, 32, 51, 52]. Research includes structural and functional analysis of 
gross anatomical differences across patients, evaluation of cellular phenotypes and 
neurotransmitter systems in post-mortem brain studies and discovery of TS-associated 
gene mutations [47, 53-56]. Neuroimaging studies have revealed a five percent volume 
reduction of the striatum across TS patients, as well as a correlation between volume 
reduction of the caudate nucleus and putamen in children and increased tic severity in 
adulthood [7]. The presence of anti-neuronal antibodies in some patients, high rates of 
maternal autoimmune disorders, and a sub-category of children in which infection is 
coincident with tic onset have prompted investigations of neuroimmune interactions [51, 
57-66]. Studies in human post-mortem brain tissue echo defects in the aforementioned 
basal ganglia regions, suggesting cellular abnormalities in the striatum, and in 
particular, decreased numbers of cholinergic tonically active neurons (CH/TAN) and two 
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types of GABAergic interneurons, the parvalbumin+ and somatostatin/nitric oxide 
synthase /neuropeptide Y+ in TS versus matched normal controls [9]. In contrast, the 
majority of striatal neurons, the medium spiny neurons, were not affected. 
Transcriptome analysis is consistent with the interneuron loss and also revealed 
prominent inflammatory changes in TS brain tissue [10]. 
 
2. Clinical Features 
2.1 Historical overview  
TS was first classified as a neurobiological disorder in the mid-1880’s by Gilles de la 
Tourette and Jean-Martin Charcot working at the Salpetriere Hospital in Paris [67, 68]. 
In the subsequent century clinical classification continued to be refined leading to 
current diagnostic criteria for childhood onset of chronic motor and vocal tics [68]. 
 
2.1.1 Disease identification 
General tic disorders affect 4% of children and are characterized by sudden, repetitive 
motor or vocal tics, which can be transient (2 weeks to 12 months) or chronic (more 
than 12 months). The first symptoms are often simple motor tics, such as eye blinking 
and facial movements, which later progress to involve additional muscles of the face, 
neck, and shoulders. Vocal tics, such as throat clearing, grunting, coughing, or sniffling, 
typically appear several years after the motor symptoms. A minority of patients has 
complex vocalizations, such as swearing (coprolalia), echolalia, and the utterance of 
words or word parts. Patients have described a premonitory sensation that occurs 
immediately prior to tics, describing tic expression as a way to relieve the premonitory 
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urge [69]. Tics typically occur in bouts, vary over time with the worst period occurring 
when the child is 10-12 years, and decrease with age [6, 70]. A minority of patients are 
chronically disabled with severe tics that continue into adulthood [71]. 
 
2.1.2 Gene identification 
To date, no gene has emerged as definitively causal. No common gene variants above 
threshold significance were identified, which could be attributed to the low risk conferred 
by such common variants, and by the limited power of discovery of rare gene 
candidates using these methods [22, 46]. Significant association of TS with 
chromosome 2 was reported, and the strength of this association increased when 
diagnosis of TS and chronic tic disorder were combined, suggesting that symptoms of 
both emerge from common underlying genetic vulnerability [72, 73]. Additional regions 
on chromosome 9 [74], 18 [75], and 22 [76-78] have been implicated. Given the 
difficulty of localizing genes via traditional linkage approaches, family-based association 
strategies are being used and have found several genes that associate with the risk of 
developing TS, including the dopamine receptor, DRD2; the dopamine transporter gene, 
DAT1; serotonin receptor, HTR2C; and gain of function alleles in the setotonin 
transporter gene, SLC6A4 [76-78]. 
 
Rare mutations were identified that appear to confer high risk of developing TS in 
particular families. Mutations in Slit and Trk-like 1 (SLITRK1) were identified after 
characterization of a chromosomal inversion in a child with TS [25]. SLITRK1 was found 
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to be expressed in brain regions implicated in TS, and in vitro assays revealed that wild-
type SLITRK1 enhanced dendritic growth compared to protein generated by a mutated 
allele [25, 47]. Very rare loss of function mutations have also been described in histidine 
decarboxylase (HDC), which catalyzes the production of histamine; IMMP2L, a 
mitochondrial pepsidase gene; and CNTNAP2, a neurexin superfamily member [25, 26, 
47, 79, 80]. It is presently unclear to what extent such rare mutations segregate with TS, 
versus co-morbid disorders such as OCD [81], or contribute to TS in the majority of 
patients [79, 80]. A recent genome wide association study of 2,434 patients identified 
rare copy number variations (CNVs) in two genomic loci: NRXN1 and CNTN6, where 
NRXN1 deletions and CNTN6 dublications were associated with a significantly higher 
risk for developing TS [23]. Furthermore, DNA sequence analysis of 674 non-multiplex 
TS trios and over a thousand control families recently confirmed an increased rate of de 
novo CNV and sequence variants in TS indviduals, suggesting that such de novo gene 
disrupting variants could be responsoible for approximately 5% of TS cases. These 
analyses resulted in the identification two high confident TS risk genes, CELSR3 and 
WWC1. Interestingly, proteins encoded by NRXN1, CELSR3, and CNTN6 are involved 
in the control of cell adhesion and/or polarity, suggesting convergent functional 
pathology [82]. 
 
2.1.3 Early treatments 
Neuroleptics became the earliest, and remain the most frequently used pharmacological 
treatment for TS, albeit with varying degrees of efficacy [83, 84]. Due to frequent co-
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morbidity of TS with obsessive compulsive disorder (OCD) and attention deficit 
hyperactivity disorder (ADHD), other early treatments include the use of adrenergic 
receptor agonists such as clonidine [84]. Standards of treament continue to be refined 
and are described in Section 7.1. 
 
2.2 Mode of Inheritance and Prevalence  
Early segregation analyses indicated that inheritance is transmitted vertically as a single 
gene of major effect. However, while some data are consistent with an autosomal 
dominant locus with sex specific penetrance, there is also evidence for intermediate 
inheritance, and many favor a multifactorial or polygenic model, suggesting that TS is 
the result of multiple genes acting together. The original description of TS included a 
familial expression pattern, and the rate of TS in relatives of probands is 10-15%, 10-
fold higher than in the general population. Inheritance is strongly genetic: tics occur in a 
second twin in 77% of monozygotic, but only 23% of dizygotic twins [45]. Yet 
environmental factors do contribute, as monozygotic twin concordance is not 100%. 
Retrospective analyses revealed lower birth weights in the more severely affected twin 
in monzygotic pairs, suggesting that prenatal factors contribute to symptom expression 
later in life [85]. 
 
2.3 Natural History  
2.3.1 Age of onset 
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Based on current classification standards, onset of TS symptoms begin in childhood 
before age 18. The mean age of onset is between 5 and 7 years, with simple motor tics 
typically preceding the onset of verbal tics by several years [86]. 
 
2.3.2 Disease evolution 
TS symptoms typically vary in frequency and intensity, increase during periods of 
fatigue or stress. Symptoms may also wax and wane spontaneously, independent from 
triggers or medication [87]. Lifetime severity may be influenced by perinatal exposures 
that presumably affect early brain development. These observations have led to a 
stress-diathesis model in which the interaction of genetic vulnerability factors with 
environmental stressors during critical periods of development affects disease onset 
and severity [69].  
 
2.3.3 Disease variants 
A potential sub-category of TS has emerged but remains controversial. Initially an 
increased prevalence of OCD was observed in Sydenham’s chorea patients with a late 
manifestation of rheumatic fever associated with a prior streptococcal infection. After an 
epidemic of streptococcal pharyngitis in Providence, Rhodes Island, tic disorders 
increased in affected children. Swedo and colleagues then proposed the existence of a 
subgroup of children with tics and/or OCD now known by its acronym PANDAS or 
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal 
infections [88]. PANDAS is defined by 5 criteria: (1) the presence of a tic disorder and/or 
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OCD; (2) prepubertal onset of neuropsychiatric symptoms; (3) history of a sudden onset 
of symptoms and/or an episodic course with abrupt symptom exacerbation interspersed 
with periods of partial or complete remission; (4) evidence of a temporal association 
between onset or exacerbation of symptoms and a streptococcal infection; and (5) 
adventitious movements (e.g., motoric hyperactivity and choreiform movements) during 
symptom exacerbation [89]. In an epidemiological study, patients were more likely than 
controls to have had streptococcal infection in the 3 months preceding onset; having 
multiple GABHS infections in the preceding 12 months was associated with an 
increased risk for TS; and overall, 12% of TS cases appeared to be GABHS-related 
[90]. The proposed pathophysiology is based on the molecular mimicry hypothesis, 
wherein antibodies produced to fight infection cross-react with epitopes in previously 
unaffected tissues. This model suggests that neuronal function is compromised in a 
manner analogous to the sequence of events proposed for Sydenham’s chorea.  
 
Therapeutic benefit was described in TS patients treated with plasmapheresis [91], and 
multiple groups found evidence for autoantibodies in the blood serum of a subgroup of 
patients [92], and additional studies have examined the involvement of cytokines, 
reporting decreased numbers of regulatory T cells [57, 58]. However, other studies have 
not supported the PANDAS hypothesis; one report found no significant difference in 
neuronal binding capacity in vitro of IgG isolated from PANDA versus TS or control 
cases [64], and in another study, PANDA cases had lower than expected exacerbation 
of symptoms and GABHS infections compared to non-PANDA cases [65]. Further 
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investigation is needed to elucidate the relationship between GABHS and TS, and to 




Clinically ascertained cases of TS are associated with a variety of other disorders. More 
than 60% of TS patients reaching clinical attention have problems with inattention, 
impulsiveness and hyperactivity, and may warrant a separate diagnosis of ADHD [49, 
93]. While the high frequency of co-occurring features (aggressiveness, depression, 
learning disabilities, and anxiety disorders) may reflect an ascertainment bias, surveys 
in community samples have also observed a higher than expected frequency of ADHD 
and disruptive behavior among children with TS [49]. As many as 30% of individuals 
with TS have sufficiently severe symptoms to warrant diagnosis of OCD, and research 
suggests that the two may be etiologically related [94-98]. 
 
3. Disease mechanisms: Pathophysiology and current research 
Several brain regions are implicated in TS, including the basal ganglia, cerebral cortex, 
hippocampus, and cerebellum [7-9, 32, 51, 52]. The basal ganglia have long been 
presumed to be central for the pathophysiology of TS, based on anatomical and 
functional studies, as well as the effectiveness of D2 blockers for the treatment of tics. 
The basal ganglia form a crossroad of converging and diverging routes for neural 
pathways projecting from the cerebral cortex to the thalamus and back to cortex [99]. 
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These pathways are somatotopically organized in parallel circuits regulating motor, 
somatosensory, cognitive, and emotional functions. When a movement is initiated, the 
inhibitory output of the direct pathway medium spiny neurons, which project from the 
striatum to the internal globus pallidus (GPi) and substantia nigra pars reticulata, is 
enhanced, releasing the inhibitory GPi brake to the precise thalamic target [99, 100]. 
These pathways are somatotopically organized in parallel circuits regulating motor, 
somatosensory, cognitive, and emotional functions. Disruption of one or more of these 
pathways is currently proposed to underlie TS symptoms. 
 
In the striatum, there are 4 main classes of striatal interneurons, identified by expression 
of calcium binding proteins and co-transmitters. These include 3 sub-classes of 
GABAergic interneurons: (1) fast-spiking parvalbumin; (2) calretinin; and (3) 
somatostatin/nitric oxide synthase/neuropeptide Y; and (4) tonically active cholinergic 
interneurons (TAN)[101-103]. Glutamatergic, cholinergic, GABAergic, and dopaminergic 
inputs converge on the spines and dendrites of the medium spiny neurons to regulate 
their output. Dopamine input and the GABAergic and cholinergic activities within the 
striatum regulate the excitatory glutamatergic input from the cortex, and ultimately the 
information processing to the thalamus [100, 104, 105]. Inhibitory parvalbumin 
interneurons are directly stimulated by the cortex and convey strong feed-forward and 
widespread inhibition to the striatal medium spiny neurons, focusing their activity on the 
most relevant inputs. A deficiency in striatal interneurons was reported in cases of 
severe unremitting adult TS, suggesting that these cells may play a role an important 
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role in the genesis and/or persistence of tics Reductions of GABAergic and cholinergic 
interneurons in the basal ganglia in TS subjects have been found, based on 
immunohistochemical labeling of post-mortem tissue with antibodies to parvalbumin, 
choline acetyltransferase [8, 9, 106], and nitric oxide synthase (FIGURE 1) [10]. The 
deficiency in striatal interneurons suggests that these cells may play a role an important 
role in the genesis or persistence of tics [8, 9, 106]. Parvalbumin+-GABAergic 
interneurons form a widespread inhibitory network responsible for maintaining inhibition 
















FIGURE 1. Cortico-striatal-thalamic circuitry and altered neuronal composition of the caudate 




In addition to decreases of parvalbumin+ interneurons in the caudate nucleus, a relative 
“excess” was found in the GPi [8]. While it is unknown whether this could be due to 
changes in cell migration, cell genesis or cell death, it is plausible that discharge 
patterns from the caudate, the GPi, or both could disrupted, leading to aberrant 
inhibition of discrete thalamic neurons and their cortical targets, resulting in tics [8]. 
Thus, deficient regulation of medium spiny neuron activity leading to disruption of their 
modulatory influence upon the thalamus and cortex is currently proposed to underlie TS 
symptoms.  
 
4.1 Human neuroimaging 
Neuroimaging of TS patients revealed larger brain volumes in prefrontal regions and 
parieto-occipital cortical regions, smaller inferior occipital volumes, and smaller caudate 
volumes [32], and caudate volume in childhood was found to inversely correlate with tic 
severity in adulthood [7]. Functional studies have found alterations in cortical-basal 
ganglia circuits, suggesting increased activity in motor, premotor, sensorimotor cortical 
regions and striatum in TS subjects [107, 108]. Compared to controls, TS subjects 
displayed heightened activity in the left caudate, which correlated with tic severity during 
pre-pulse inhibition to startle tasks [109]. In addition, increased metabolic activity in the 
right caudate was found during tic suppression, which negatively correlated with tic 
severity [110]. As tic severity increased, the signal changes decreased, suggesting that 
tics are due to a failure of inhibitory systems [110, 111]. This finding concurs with the 
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decreased number of inhibitory interneurons found in the TS caudate in the -mortem 
studies described above [9, 10].  
 
Further support for the influence of sensorimotor cortical regions on TS is evident from 
additional imaging studies that revealed cortical thinning in the sensory and motor 
regions in children with TS [112]. And while some regions – including the lateral 
temporal and inferior parietal cortices and the inferior primary sensory cortex – exhibited 
comparable cortical thickness across both TS children and control children, longitudinal 
analysis of these cohorts revealed that control children exhibited cortical thickening with 
age while the TS children did not [112]. Previous findings via transcranial magnetic 
stimulation showed decreased intracortical inhibition in motor cortices in TS children, 
suggesting a potential reduction in GABAergic interneurons in these regions [113]. 
Postmortem studies are needed to investigate the cellular abnormalities underlying 
these neuroimaging findings. The correlation between cortical thickness of sensorimotor 
regions and tic symptoms reiterates a prominent role for these brain regions in the 
clinical manifestation of TS.   
 
PET and SPECT studies have suggested increased density of striatal dopamine 
receptors in TS subjects [107, 108]. Involvement of dopamine signaling is also indicated 
by considerable clinical pharmacological data: (1) the most consistently effective drugs 
for suppressing tics are dopamine D2 receptor blockers; (2) tics may worsen following 
exposure to high doses of stimulants known to increase central dopaminergic activity; 
 24 
(3) withdrawal from neuroleptic treatment is often accompanied by a rebound in tic 
symptoms presumably due to heightened receptor sensitivity and/or up-regulation of 
post-synaptic dopamine receptors; (4) elevated levels of a dopamine metabolite, 
homovanillic acid, have been found in the cerebrospinal fluid of TS subjects [114, 115]. 
 
Other neurotransmitter systems have been implicated based on immunohistochemical 
and transcriptome studies, as described earlier, which include GABA, glutamate and 
acetylcholine, that are all known to play a role in cortico-striato-thalamo-cortical circuitry 
(FIGURE 1) [104].  
 
4.2 Animal models 
In vitro models enable the advantage of studying the genomics and genetics of complex 
circuitries involved in mechanisms underlying Tourette syndrome, but meet their 
limitations when we try to understand the downstream effects of genetic alterations 
especially in regard to tics and behavioral comorbidities. Modeling Tourette syndrome in 
rodents and primates allows us to mimic a disorder by introducing genomic or drug 
induced alterations, study the resulting effects and subsequently develop strategies to 
rescue the phenotype. The gain of those critical insights is of tremendous value to be 
able to improve current therapies and thus the quality of life for patients. 
As an example, current research includes genetic modeling to understand the roles of 
SLITRK1 and histidine decarboxlyase (Hdc) in mice [25]. Tic-like behavior in form of 
excessive grooming was observed after the induction of acute stress by cued fear 
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conditioning in Hdc knockout mice [26, 56]. Administration of low doses of picrotoxin 
into the dorsal striatum and the sensorimotor cortex induce non-rythmic tic-like 
movements in mice. This phenotype was rescued by the administration of muscimol, a 
GABA-A agonist, again suggesting a connection between alteration of the GABAergic 
system and the development of tic-like movements [116, 117]. Models of striatal 
interneuron ablation are being evaluated for their potential to evoke stereotypic 
behaviors. Stereotopy can be induced through stimulant exposure, which affects 
expression of immediate early genes and generates an imbalance of striatal activity 
within striosome versus matrix compartments [118, 119]. In rodents and monkeys, low 
doses of agents that activate the dopamine pathways (i.e., amphetamine, apomorphine, 
and cocaine) increase locomotion while elevated doses produce stereotypic behaviors. 
Animal models manipulating the serotonin system by administrating serotonin agonists 
should be considered with caution due to potential nonspecific effects [117].  
 
Neuroimmune modeling has revealed induction of stereotypic behavior in rodents 
following striatal infusion of serum from TS patients with high levels of anti-neuronal 
autoantibodies, but not after infusing serum from controls or TS patients with low levels 
of anti-neuronal autoantibodies [120, 121]. Subsequent studies were not able to 
reproduce these results, and additional research is necessary to determine whether 
autoantibodies play a role in some TS cases [122]. Interestingly, in vitro studies have 
shown that immune modulation is sufficient to alter signaling mechanisms critical for 
parvalbumin neuron function [123, 124]. Interestingly, in vitro studies have shown that 
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immune modulation is sufficient to alter signaling mechanisms critical for parvalbumin 
neuron function [123, 124].  
 
4.3 In vitro models 
Currently, with the rise of stem cell-derived neural organoids, there is great promise for 
disease modeling in in vitro systems to elucidate the etiology of TS. Although there are 
no studies published to date featuring such TS model systems, the potential is vast for 
stem cell strategies to uncover new biomarkers and/or neural mechanisms involved in 
TS. Human induced pluripotent stem cell (iPSC)-derived neural organoids are 3D 
multilayered cellular aggregates capable of recapitulating human embryonic 
development. With its childhood on-set as early as 3 years of age, TS is categorized as 
a neurodevelopmental disorder; however, symptoms may be delayed with respect to the 
causal mechanisms underlying the disorder, and therefore the actual “age of onset” is 
unknown. Human neural organoids could provide the first accessible window into 
human embryonic and fetal development, thereby facilitating study across patient and 
control groups to untether the complex etiopathophysiology of TS. Recent advancement 
in this technology mimic both cortical and basal ganglia development in these neural 
organoids [16, 18, 125], allowing the assessment not only of individual regional 
development across patients and controls, but also the more complete telencephalic 




The additional advantage of using stem cell strategies include the important 
foundational fact that the cell samples are obtained directly from living TS individuals. 
While large-scale therapies are possible from this approach as well, the patient-
specificity of the technology allows for an uncovering of an individual’s 
neurodevelopment that could ultimately benefit the most severe of TS patients to 
potentially illuminate individualized treatment methods. 
 
Both scientific and clinical fields could benefit from investigation and modeling of TS in 
neural organoids. Such research could elucidate critical biomarkers in disease 
pathogenesis as well as therapeutic targets, and could even contribute to new 
diagnostic opportunities in children.  
 
5. Differential Diagnosis  
Many diseases can manifest with tics, such as Huntington’s disease and stroke, but do 
not typically have pediatric onset. Others movement disorders, including Sydenham’s 
chorea, the dystonias, and some rare genetic conditions may require more careful 
evaluation [126, 127]. Events such conditions as carbon monoxide poisoning are 
germane to children and may present with transient tics; however, these are 




There are presently no molecular, neuroimaging, or physiological mechanisms that can 
reliably aid in TS diagnosis. Instead, diagnosis relies on clinical evaluation, using rating 
systems such as the The Yale Global Tic Severity Score [50]. The YGTSS rates 
multiple features of symptoms including the number, frequency, intensity, and 




7.1 Standard of care 
The goal of treatment is to achieve a balance between adequate tic control and 
minimizing side effects, rather than tic eradication. Several medications (Table 1) have 
been used for the treatment of tics, although few have been adequately tested in 
placebo-controlled studies [128]. Typical antipsychotics such as haloperidol and 
pimozide were the first medication demonstrated to be  effective for tics. Haloperidol is a 
potent postsynaptic D2 receptor blocker often effective at low doses but associated with 
a high frequency of adverse effects. Pimozide is also effective but at high doses, or in 
combination with drugs that inhibit CYP3A4, QT prolongation is a potential 
consideration and cardiac monitoring is warranted [128].  
 
Atypical neuroleptics have also been used for tic treatment. Tiapride and sulpiride, 
unavailable in the United States, have shown positive results in controlling tics; 
however, both require more study to confirm their efficacy. The D2- and 5HT2- blocking 
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agents Risperidone and Ziprasidone were found to be effective in placebo controlled 
studies [129, 130]. Ziprasidone has a unique receptor profile including 5-HT1A-agonist 
and modest norepinephrine and serotonin reuptake blocking properties, suggesting that 
it may have additional anxiolytic and antidepressant effects [128].  Aripiprazole, which 
acts a partial agonist at the D2 receptor also has demonstrated efficacy in treating tics 
[131, 132].   Atypical antipsychotics are associated with a poor side-effect profile 
including weight gain, increased risk of metabolic syndrome and diabetes so even 
though they are the medications with the greatest demonstrated efficacy in reducing 
tics, they are often not used first-line, especially in children [133].  
 
Adrenergic alpha 2 agonists are frequently used in the treatment of tics or ADHD that is 
commonly associated with TS. Clonidine was introduced as a treatment for tics in the 
1970s and has shown modest benefits for ADHD. Although unlikely to be as effective as 
D2 blocking antipsychotics in reducing tics, it is commonly used in children with TS due 
to concerns about long-term exposure to neuroleptics. In the 1990s another alpha-2 
agonist, guanfacine, was introduced for the treatment of ADHD in children with TS, and 
in a randomized clinical trial was superior to placebo for ADHD and tic symptoms [134].   
Alpha-2 agonist medications have been demonstrated to be effective in reducing tic 
symptoms but primarily for children with comorbid ADHD [135]. 
 
Several other medications have been tried with varying success in their capacity to 
suppress tics including topiramate [136], cannabis-derived medications [137, 138], 
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vesicular monoamine transporter 2 (VMAT2) inhibitors [139-141] and ecopipam (a 
D1/D5 receptor antagonist) [142]. These emerging treatments are discussed in section 
7.3. In addition to pharmacological strategies, there is growing interest in behavioral 
interventions such as parent training, anger control training and habit reversal training 
[143, 144]. Clinical trials have found behavioral therapy particularly habit reversal 
therapy to be effective, with some patients demonstrating continued improvement 6 
months post-treatment [145-147].  The benefits of habit reversal therapy for the 
treatment of tics in terms of effect size seem to be similar to the most effective anti-tic 
medications [148].  However, dissemination remains a major challenge to the 














TABLE 1. Current pharmacological treatments for Tourette syndrome 
 







Many side effects including sedation, 
dysphoria, cognitive dulling, weight 
gain, parkinsonism, dystonia, 
dyskinesia, and akathisia 
Pimozide 0.5-4 mg/day QT prolongation at high doses or in 
combination with CYP3A4 inhibitors 
Atypical neuroleptics 
(D2 blockers) 
   
   
Aripiprazole 5-20 mg/day Low frequency of neurological side 





mg/day in 2 
divided doses 
Low frequency of neurological side 
effects; drowsiness and weight gain 
are common. Also 5HT2 blocker 
Ziprasidone 
[129] 
  Low frequency of neurological side 
effect and less weight gain than most 




Rhabdomyolysis, QT prolongation 
Sulpiride 0.1-0.8 g/day 
Not available 
in the US 
Low frequency of neurological side 
effects 





mg/day in 3-4 
divided doses 





in 3 divided 
doses 
Minimal side effects; benefit for ADHD 
 
 
7.2 Failed therapies and barriers to treatment development  
Treatment of TS is challenging, as its natural course is variable. Even without treatment, 
symptoms reduce or resolve by young adulthood in the majority of patients. While 
emerging studies continue to support a standard of care for TS, these have also 
revealed an unusually robust placebo response [150-153]. This presents a potential 
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barrier to identifying effective therapies, and has been noted in other disorders that 
involve the basal ganglia [154].  
 
7.3 Therapies under investigation 
Preliminary results in severe, refractory TS cases suggest that procedures such as 
neurofeedback, transcranial magnetic stimulation, and deep brain stimulation may have 
a place in the treatment of TS [100, 155-158]. Although offering great promise for the 
treatment of severe TS cases, consensus has not yet been achieved, for instance, on 
the optimal placement of the deep brain electrodes, and much needs to be learned 
about how best to apply these technologies  [159].  Several medications such as 
topiramate [136], dronabinol [160], VMAT2 inhibitors [139-141], ecopipam (a D1/D5 
antagonist) [142] have demonstrated efficacy in small, randomized-controlled trials or in 
large open-trials.  Larger, multi-site, placebo-controlled studies are currently ongoing to 
more clearly determine the efficacy of these agents in the treatment of tics. 

8. Conclusions 
Research over the next decade is likely to build on the recent discoveries in 
neurobiology, epidemiology, genomics, genetics, and neuroimaging, and lead to better 
treatments. New psychopharmacological agents based on a better understanding of the 
neurobiology and will be used in combination with behavioral interventions. Moreover, 
longitudinal clinical investigations into the phenomenology and natural history may 
provide additional clues on the biological processes involved. The cellular abnormalities 
that have been detected in patient’s post-mortem brains will serve as a guide for the 
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development of animal models, which will allow investigators to explore specific 
hypotheses. In addition, induced pluripotent stem cells can be generated directly from 
patients, which may allow to reproduce aspects of TS neurobiological abnormalities in 
vitro using the organoid system, facilitating the generation of large scale genetic and 
drug screen to find patient-tailored treatments [161]. Through these combined efforts, 
we will eventually come to a more complete understanding of the neurobiological 
mechanisms and treatment of TS.  
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Chapter 1B: Cellular and Molecular Pathology of Tourette 
Syndrome 
The following section focuses on the current postulates in the field surrounding TS 
etiology. This section compiles current data that detail deficits and abnormalities seen 
across TS individuals, especially unremitting adult patients. Through this information, 
the heterogeneity of the disorder can be appreciated and the gaps in our understanding 
are explained. This section establishes a critical empirical foundation for the motivation 




The basal ganglia are considered a central station in the regulation of motor programs.  
Although the function of the basal ganglia is not entirely known, their circuitry has been 
extensively investigated. The basal ganglia are a set of nuclei situated deep within the 
cerebral cortical hemispheres. In the basal ganglia, a large number of cortical and 
subcortical excitatory inputs converge on a relatively small number of neurons whose 
firing represent complex temporal coincidences of neural activity in a vast number of 
afferent regions. The main function of the basal ganglia is to exert negative regulation 
by tonically inhibiting ongoing neural activity in the thalamus.  However, arousing stimuli 
that travel through the ascending reticular activating system, and those that, having 
been associated with the anticipation of rewards, activate the dopamine system, 
temporarily suppress the negative regulation of the basal ganglia, resulting in facilitation 
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of sensory and motor functions. In this way the basal ganglia regulates the initiation and 
execution of learned actions, such as habits, and in general facilitate the integration of 
voluntary and involuntary segments of cognitive and motor activity.  
 
Patients with Tourette syndrome (TS) have a decreased volume of the caudate (CD) 
and putamen (PT) nuclei in the striatum [31, 32], the first station of the basal ganglia 
receiving inputs from the cerebral cortex, the thalamus and midbrain dopamine neurons 
(Figure 11.1). Although both cortical and cerebellar anatomical abnormalities have been 
described in neuroimaging studies of TS individuals [112, 162-164] (reviewed in [68], 
the decrease in caudate volume has particular relevance since the reduced volume of 
the caudate nucleus in childhood correlates significantly and inversely with the severity 
of tic and obsessive compulsive disorder (OCD) symptoms in early adulthood [7]. 
Furthermore, in monozygotic twins discordant for severity of TS, the right CD was 
smaller in the most severely affected twin pair [165]. Overall, the neuroimaging studies 
suggest that the basal ganglia are a central component of the pathophysiology of TS 
(see also Chapter 12). 
 
Basal ganglia anatomy and circuitry  
The hypothesis that an inherited or developmentally acquired dysfunction of the basal 
ganglia causes TS is in agreement with studies in a variety of animal models suggesting 
that the basal ganglia are the main “integrators” of higher motor and cognitive functions 
(see also Chapter 15). One of their key functions is to select among ongoing 
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sensorimotor activities based on their salience and motivational value, by integrating the 
activity of the dopamine system, which is activated by the anticipation of rewards, with 
sensory, motor and attentional systems, which are channeled to the striatum via the 
thalamus and the cerebral cortex. Indeed, the CD and PT receive direct inputs from the 
cerebral cortex, the thalamus and midbrain dopamine neurons. The final common 
output of the basal ganglia is the Internal Segment of the Globus Palludus/Substantia 
Nigra Reticulata (GPi/SNr), which tonically inhibits the ventral anterior and ventral lateral 
(VA/VL) and intralaminar (IL) thalamic nuclei, suppressing motor activity (Figure 11.1A). 
It has been hypothesized that failure to integrate sensorimotor information within the 
basal ganglia may lead to the development of tics (see Chapter 12 on 
Electrophysiology). 
 
The medium spiny neurons (MSNs) of the CD and PT are projection neurons of the 
striatum that form two major pathways, the indirect and direct pathway, which have 
opposite effects on the GPi/SNr and behavior [30]. The direct pathway inhibits the 
GPi/SNr, resulting in excitation of thalamic neurons and facilitation of motor behavior; 
conversely, the indirect pathway indirectly excites the GPi/SNr by inhibiting the 
subthalamic nucleus, inhibiting motor behavior (Figure 11.1A).  
 
The striatum, based on its cortical inputs, contains three major functional territories, the 
associative, sensorimotor, and limbic (see Figure 10.1B).  These functional domains are 
largely segregated throughout the striatum. The associative territory comprises almost 
 37 
the whole extension of the CD and the precommissural PT. The sensorimotor domain 
includes the dorsolateral aspect of the CD head, part of the dorsal precommissural PT 
and the entire postcommissural PT. The main component of the limbic striatum is the 
nucleus accumbens, the deep layers of the olfactory tubercle, and the ventral part of 
both the CD and the PT [166]. The cortico-striatal projections terminate in the form of 
clusters of various sizes, whose distribution closely follows that of the two major striatal 
chemical compartments – the striosomes and the extrastriosomal matrix. Studies of the 
non-human primate have shown differential patterns of connectivity for the striosome 
and matrix compartments in the striatum [167, 168]. Striosomes are interconnected with 
regions linked to limbic circuitry, and the matrix is interconnected with sensorimotor and 
associative cortical circuitry.  
 
Interneurons in the basal ganglia and their functional implications for disorders 
Recent evidence has shown important modulatory roles of striatal interneurons on the 
direct and indirect pathways. There are 4 classes of interneurons within the striatum, 
identified by their expression of calcium binding proteins and co-transmitters: (1) 
Parvalbumin (PV+); (2) Calretinin (CR+); (3) Somatostatin/Nitric Oxide Synthase 
/Neuropeptide Y (SST+/NOS+/NPY+); and (4) Cholinergic or Choline acetyl transferase 
(ChAT+).  
 
The fast-spiking, PV+ interneurons form a non-habituating striatal inhibitory network [34, 





Figure 11.1. The Basal Ganglia.A, Schematic outline of the basal ganglia circuitry.Red, 
excitatory neurons; blue, inhibitory neurons; green, cholinergic neurons, orange, dopaminergic 
neurons. Parvalbumin (PV) interneurons mediate the cortical feed-forward inhibition upon 
medium spiny neurons (MSNs) of the striatopallidal direct pathway, resulting in inhibition of 
voluntary movements. Cholinergic (Ch) interneurons enhance the responsiveness of medium 
spiny neurons (MSNs) of the striatonigral indirect pathway, resulting in movement suppression. 
B, Functional subdivisions of the basal ganglia projected on a lateral view of the basal ganglia 
andtheir cortical afferent systems. Based upon Parent et al (1990) and Bernacer et al (2007). 
PV+ cells receive strong cortical synaptic input [33] and respond with shorter latency 
that MSNs to cortical stimulation, preferentially suppressing the activity of MSNs of the 













The cholinergic interneurons have been long thought to play a role in associative 
learning [169] and fire tonically with periodic pauses, which temporally coincide with 
burst firing in dopamine neurons. Cholinergic neurons receive a strong excitatory input 
from the median-parafascicular complex (IL) nuclei of the thalamus [38] (Figure 11.1 A).  
Cholinergic interneurons excite SST+/NOS+/NPY+ striatal interneurons, which in turn 
inhibit MSN [170]. Hence, MSNs can be inhibited directly by PV+ interneurons and 
indirectly by cholinergic neurons via the SST+/NOS+/NPY+ interneurons. 
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Most striatal MSNs are silent except for those MSNs that are involved in the initiation of 
particular movements and related cognitive activity. This global suppression of MSN 
activity is caused by activation of the cortex and intralaminar nuclei of the thalamus, 
which, in turn, feed upon the above-described prominent inhibitory systems, the PV+,  
SST+/NOS+/NPY+, GABAergic, and cholinergic interneurons, respectively. 
Consequently, any interference with striatal interneuron activity, or with their activation 
by their cortical and thalamic afferents, is expected to cause aberrant movement 
initiation, such as dyskinesias and tics. 
 
Unbiased and systematic neuropathological studies of TS revealed a disturbance 
in number or maturation of regulatory basal ganglia interneurons 
Our group reported the first unbiased and systematic neuropathological study of TS in 
2005 [8]. It showed a disturbance in number or maturation of PV+ interneurons using 
stereology in postmortem basal ganglia tissue from three adult subjects with severe, 
persistent TS as compared with age- and sex-matched normal controls (NCs).  
Immunostaining for SP and met-enk, neuropeptides contained within MSN of the direct 
and indirect pathways, respectively, showed no differences in the apparent density or 
distribution of MSNs between NC and TS [8].   
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Consistent with these preliminary results, in a subsequent more comprehensive study 
involving 5 cases of TS and matched NCs we found a 55.7% decrease in the density of 
PV+ interneurons in the striatum of TS individuals (Figure 11.2) [9].  
 
In this study, we also examined two other classes of interneurons, the medium sized 
CR+ and the large size ChAT+ cholinergic interneurons, as well as DARPP-32+ MSNs 
and cresyl violet staining to assess the total number of neurons.  There was no 
difference in the number of medium-sized CR+ interneurons (10-20 μm) between NC 
and TS individuals, whereas the density of large-sized ChAT+ cholinergic interneurons 
was decreased by 49.4% in the TS striatum (Figure 11. 2) [9]. The density of cresyl 
violet-stained neurons in the striatum was not significantly different between NC and TS, 
indicating that this combined decrease in PV+ and cholinergic interneurons in the 
striatum of TS patients is not attributable to a generalized neuronal loss.  This specificity 
of changes in PV+ and cholinergic neuron density was also confirmed using DARPP-32 
antibodies, demonstrating no significant change in MSNs. 
 
We analyzed the distribution of cholinergic interneurons in the three main functional 
subdivisions of the striatum, namely the associative, sensorimotor, and limbic regions, 
to evaluate physiological implications of the above changes for cholinergic circuitry [9]. 
The associative region showed the most pronounced decreases in cholinergic neuron 
density (60.0% decrease, p < 0.0005) followed by the sensorimotor region (44.7% 
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decrease, p = 0.008) whereas the limbic region was not significantly different between 
TS and NC individuals (p = 0.402).  
 
The remaining class of 
GABAergic interneurons, 
containing SST+/NOS+/NPY+ 
interneurons,  was assessed 
using NOS immunostaining 
and stereology. In the Kataoka 
et al. study there was a strong 
trend toward a decrease of 
NOS+ cell densities in the 
striatum of TS individuals (-
45.4 % in the CD, -53.2 % in 
the PT), but this did not reach a 
statistically significant 
difference (p = 0.0556 in the 
CD, p = 0.0542 in the PT). In a 
subsequent study [10] we were able to show a significant decrease in this class of 
interneurons at both the RNA and protein levels (Figure 11.2). This decrease  is 




Figure 11.2. Cellular abnormalities In TS. Top, summary of 
stereological counts in postmortem brain tissue of TS and matched 
controls (NC). Note different scale of the Y axis for MSN and 
interneurons. Bottom, representative immunostaining and cell 
density counts of NOS+ interneurons in the CD. Each dot 
represents an individual subject. PV= Parvalbumin interneurons;  
ChAT= choline-acetyltransferase interneurons; NOS= nitric oxide 
synthase interneurons. For more details see Kataoka et al (2010) 





Fig. 11.3. Immunological alterations in TS caudate nucleus.  Left, 
density counts of CD45+ cells, a generic marker for hematopoietic cells 
including lymphocytes and monocytes;  Middle, density of IBA+ cells, a 
marker for microglia (middle); Right, process length of IBA+ cells, which 
is inversely proportional to their activation. Each dot is a single subject. 
For more details see Lennington et al (2016). 
induced suppression of striatal activity, and thus act downstream of cholinergic cells in 
the striatal circuitry [170]. 
 
Transcriptome analyses   
Transcriptome profiling was carried out in bulk CD and PT tissue of nine TS and NC 
matched for sex and age [10]. A total of 1,131 genes were found to be differentially 
expressed between TS and NC, including 309 that were down-regulated and 822 that 
were up-regulated (FDR<0.05). For the 309 down-regulated genes, the top IPA 
BioFunctions were related to nervous system development and function, neurological 















These categories included genes involved in G-protein coupled receptors and 
GABAergic receptor signaling (Table 1). Several of the down-regulated genes in TS 
were involved in neurotransmitter biosynthesis, transport, and function of several 
classes of basal ganglia interneurons, including ChAT, the vesicular acetylcholine 
transporter SLC18A3, the choline transporter SLC5A7, and LHX8, a gene critical for 
forebrain cholinergic neuron development [171, 172] (Table 2). Additionally, the data 
revealed reduced expression of NOS1, NPY, and SST, which together are co-
expressed in a class of GABAergic interneurons of the basal ganglia (Table 2). This was  
paralleled by a decrease in density of NOS immunoreactive cells in both in the CD (-
37.6%, p=0.012) and PT (-42.2%, p=0.012) of TS versus NC (Figure 11.2). These 
results confirmed the decreases in cholinergic and GABAergic interneuron-specific 
transcripts in the striatum. 
 
Top biofunctions for the up-regulated genes were inflammatory response and immune 
system-related genes [10] (Table 1). Upregulated genes included major 
histocompatibility complex class II molecules; immunoglobulin chains; Toll-like 
receptors; and components of cytokine signaling (several CCL and CCR1,2,3 and 5; 
CSF1R and CSF3R; several interleukins and their receptors). We also found an 
increase in several transcripts related to the microglial/macrophage lineage, such as 
IBA (+2.39, FDR 5.63E-07) and CD68 (+2.03, FDR 6.11E-06). Immunolabeling of IBA in 
the caudate revealed no change in the density of IBA+ cells; however, we found 
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significant decreases in IBA+ cell body size and decrease in IBA+ cell projections, 
indicative of microglia activation in TS basal ganglia (Figure 11.3) [10]. In addition, cells 
positive for CD45/PTPRC, a transcript expressed by all differentiated hematopoietic 
cells including lymphocytes, monocytes, and macrophages, were significantly increased 
in density in TS (Figure 11.3). Previous analyses have suggested dysregulated immune 
response in TS, including alteration in TNFa in the blood [57]. All together these 
changes indicated chronic inflammatory changes, whose cause or cellular origin is 
presently unknown.  
 
In summary, combined immunocytochemical and transcriptome analyses identified two 
potential abnormal pathophysiological events in TS: loss/dysfunction of striatal 
interneurons, and striatal inflammation. However, their relative contribution to disease 
mechanism and to the clinical manifestations of TS is presently unclear, and it is 
unknown if they have a reciprocal relationship (i.e., is one a secondary consequence of 
the other, or are they independent?). For example, striatal inflammation could lead to a 
host of secondary phenomena including oxidative stress and neuronal death, leading to 
the observed neuronal loss and the ensuing dysfunction of neuronal activity in the TS 
striatum. Alternatively, these could represent independent phenomena, as suggested by 
the lack of a correlation between the two sets of transcripts across subjects [10]. In 
addition, microglia/immune dysregulation has been observed in postmortem brain tissue 




Potential role of the cerebral cortex in tic behavior 
In primates, somatosensory cortical areas, encompassing Brodmann areas 1-3 (BA 1-3) 
and motor/premotor cortical areas (BA 4-6) send projections primarily to the PT, 
whereas the dorsolateral prefrontal cortex (PFC) projects to the CD [178-181]. There 
are at least four motor areas in humans, the primary motor (MI), premotor (PM), 
supplementary motor area (SMA) and cingulate motor areas (CMA) (for a review, see 
Roland and Zilles, 1996). All these areas are activated bilaterally during the planning 
and execution of simple and complex movements, with the exception of primary motor 
cortex (BA4) which is predominantly activated contralaterally. It is thought that while MI 
is involved in movement execution, the PM is activated by planning movements and in 
general whenever movements are guided by sensory information, as in tracking or 
manipulating objects. In contrast, the SMA is activated by the performance of self-
paced, over-learned (automatic) motor sequences such as fluent speech as well as by 
imagining or planning learned sequences; moreover, stimulation of the SMA can arrest 
movement.  
 
Activity in this distributed sensorimotor circuit and in an additional set of territories was 
detected by positron emission tomography (PET) and functional magnetic resonance 
imaging (fMRI) before and during the occurrence of tics (see also Chapter 12). Tic-
correlated activity was seen in MI, PM, SMA, rostral part of dorsolateral prefrontal 
cortex, the Broca area and frontal operculum, anterior cingulate, the insula, claustrum, 
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putamen and caudate [52, 182-184]. While activity was stronger in TS in some of these 
regions, it appeared to be weaker in portions of the circuitry that exert negative control 
over motor pathways, notably the caudate and anterior cingulate cortex; furthermore, 
less activity in these regions accompanied more severe tic symptoms [184]. The tic-
associated activation of the phylogenetically older insular cortex, which is involved in the 
integration of internal motivational states with executive functions, has been 
hypothesized to contribute to the uninhibited behavior of TS [52, 182]. Increased 
excitability of primary motor cortical areas has also been detected in a transcranical 
magnetic stimulation study of TS individuals [113] (See also Chapter 11). Abnormal 
excitability of these cortical regions could be attributed to decreased intracortical 
inhibition or to increased excitability of thalamic afferents. Together, these studies 
suggest that increased activity in motor, somatosensory and paralimbic areas may be 
involved in tic generation and may account for the irresistible urge that accompanies tic 
behavior, whereas lower activity in prefrontal circuits subserving executive functions 
may result in poor tic control. A neurochemical evaluation of frontal cortical regions from 
post-mortem tissue in 3 cases of TS have revealed neurotransmitter system 
dysfunctions in TS, notably dopamine, dopamine type 1 and 2 receptors, dopamine 
transporter, adenosine type 2 receptor and vesicular monoamine transporter [185, 186]. 
However, given the low number of subjects, the significance of these findings for TS 
remains to be established. 
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Stern et al (2000) suggested the intriguing hypothesis that “tics may represent a 
paradoxical state in which brain regions …normally associated with a subjective 
experience of volition as they initiate action, are not operating under the volitional 
control of the patient.” Although the neural substrate for the subjective experience of 
‘lack of control’ experienced by the patients is unclear, a reasonable hypothesis is that 
there is an abnormal integration between premotor and other brain regions in TS, 
particularly the prefrontal cortex (PFC), a heterogeneous set of areas that are important 
for the voluntary control of motor routines [187, 188]. Dorsal PFC areas respond to 
temporal contingencies, evoke memories and emotions, monitor errors, and correct 
motor sequences (executive functions). This is consistent with the strong engagement 
of wide regions of the PFC during tic suppression [110], and with observations that 
increased alpha frequency band coherence (a measure of functional connectivity) was 
detected between prefrontal and sensorimotor areas in patients with TS in connection 
with the successful inhibition of unwanted movements [189].  
 
To assess whether the decrease in PV+ cells was specific to the striatum, we estimated 
their density in the insular and cingulate regions of the cerebral cortex, two areas that 
are prominently activated during tic behavior and are implicated in TS. We found a trend 
toward a decrease in the insular cortex, but overall no statistically significant decrease 
(not shown). The low number of samples again precludes a definite conclusion; 
however, we note that in contrast to a clearly visible trend in the insular cortex, no such 
trend was observed in the cingulate cortex. These data suggest the intriguing concept 
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that TS individuals might exhibit differences in the number of inhibitory cortical 
interneurons in specific regions of the cortex. This is consistent with several transcranial 
magnetic stimulation (TMS) studies in which TS individuals have shown  reduced short-
interval cortical inhibition (SICI), a paradigm which assesses the functional recruitment 
of intracortical interneurons (see Chapter 12).  Future analyses involving these as well 




The neuroimaging analyses, our postmortem brain analyses, and the neurophysiology 
of the thalamo-cortical-striatal feed-forward circuit, all implicate the basal ganglia and 
particularly the PV and cholinergic neurons in the pathophysiology of tic behavior.  
 
Cortico-striatal feed-forward inhibition and PV+ GABAergic neurons. 
Neurophysiological studies in striatal slices and whole-animal recording support the idea 
that PV+ striatal interneurons exert a strong “no go” inhibitory influence upon motor 
activity in response to cortical activation. PV+ cells receive direct, strong cortical 
synaptic input [33] and respond with shorter latency than MSNs to cortical stimulation 
driving powerful feed-forward inhibition throughout the striatum [36, 190] (Figure 10.1).  
PV+ cells also drive the synchronous oscillations in membrane potential and electrical 
activity involving the cortex and striatum [191]. However, behavioral evidence for their 
implication in TS-related behaviors is still lacking.  These cells are crucial for overall 
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regulation of excitatory activity in multiple regions of the CNS, and thus animals with 
widespread loss of PV+ neuron activity develop seizures, confounding the overall 
picture.  
 
Developing mice with selective PV+ neuron inactivation or loss is a promising strategy 
that may eventually yield insights into the roles of PV+ neurons in the basal ganglia and 
in TS. For example, the dt(sz) hamster, harboring an autosomal recessive genetic 
mutation which results in episodes of dystonia and choreoathetosis, develops 
paroxysmal dystonia at 30-40 days of life, concomitant to an increase in the activity of 
MSNs which has been hypothesized to be based on a deficit of striatal (but not cortical) 
PV+ interneurons [192]. Interestingly, there is a spontaneous remission of paroxysmal 
dystonia in older dt(sz) hamsters, coinciding with a normalization of the density and 
increased arborization of striatal PV+ cells [193]. The data suggest that abnormal 
maturation or survival of striatal PV+ interneurons plays a critical role in the development 
of paroxysmal dystonia, but interestingly, this can be reversed later in life. While the 
data are still inconclusive given the possibility of other intervening factors in these 
mutants, a recent report suggests that a novel compound, selectively inhibiting the firing 
of fast-spiking PV+ neurons infused into the sensorimotor striatum, induces dystonic-like 
movements in mice [37]. Together with the physiological evidence, these animal models 
strongly suggest that a dysfunction of PV+ cells may cause a hyperkinetic movement 
disorders and that these cells represent a therapeutic target for TS. In general, these 
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findings support the conclusion that PV cells are essential to avoid reverberant activity 
and obtain selective activation of MSNs in the striatal neuronal network. 
 
Thalamo-striatal feed-forward inhibition and ChAT neurons 
Cholinergic neurons of the striatum are activated by prominent projections from VA/VL 
and centromedian-parafascicular (intralaminar) complex of the thalamus [194, 195] 
(Figure 10.1). The VA/VL thalamic nuclei process sensorimotor information and, in turn, 
receive inhibitory projections from the GPi [196, 197]. GPi projection neurons exhibit 
high frequency tonic and oscillatory activity. Cholinergic neurons are also the main 
target of thalamo-striatal afferent fibers originating from the intralaminar nuclei, which 
are the rostral component of the reticular activating system [198]. Thus, cholinergic 
neurons receive information about sensory stimulation and ongoing activity as well as 
the arousal state of the animal. In turn, cholinergic interneurons regulate the firing of the 
PV interneurons acting through nicotinic and muscarinic receptors [39] and also excite 
SST/NOS/NPY interneurons through nicotinic receptors. Excitation of these inhibitory 
striatal interneurons results in a secondary prolonged GABA-mediated inhibition of 
MSNs [170, 199, 200]. Other actions that have been attributed to cholinergic cells are a 
transient presynaptic inhibition of corticostriatal terminals impinging on MSNs of both 
pathways, and a direct facilitation of activity of MSNs of the indirect pathway via 
postsynaptic M1 class muscarinic receptors [199-201]. Hence, cholinergic interneurons 
exert complex actions on the striatal circuitry and their role is not completely 
understood. It would be interesting to know whether the inhibition of MSNs affects 
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preferentially those of the direct pathway; if true, an inhibition of the direct pathway 
together with a facilitation of the indirect pathway would profoundly excite the GPi/SNr 
output neurons and thus inhibit motor behavior. Based on the findings of the reduction 
of cholinergic interneurons in postmortem human striata [9, 10], Xu et al [202] 
developed a mouse model studying the effect of 50% reduction of ChAT+ interneurons, 
induced by diphtheria toxin, in the dorso-lateral striatum (DLS, corresponding to the 
human putamen) and dorso-medial striatum (DMS). The reduction of ChAT+ 
interneurons neither impacted GABAergic cells nor PV+ interneurons. However, after 
acoustic startle stimuli, the DLS, but not DMS injected mice displayed tic-like stereotypy, 
which was not observed at baseline. Mice with ChAT+ neuron deficiency in the DLS 
performed significantly worse in a motor learning rotorod behavioral paradigm, but 
drastically improved over time. D-amphetamine administration caused enhanced 
locomotion in ChAT+ interneuron deficient mice as well as in the control group. 
Interestingly, only mice with a loss of ChAT+ cells in the DLS displayed repetitive 
grooming behavior. Although these data imply a role of cholinergic neurons in the DLS 
in tic-like behavior in mice, it is still unclear how abnormalities in other cell types and 
observed inflammation contribute to the development of TS and cause an imbalance of 
the corticostriatal circuitry. 
 
Possible Causes 
Given the retrospective nature of our data, it is impossible to discern whether the 
observed changes in inhibitory and cholinergic interneurons are causally related to TS, 
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represent long term consequences of a remote pathophysiological event, or represent a 
secondary effect totally unrelated to the mechanism of disease. However the defects in 
interneuron number is likely to compromise the overall ability of the striatum to organize 
ongoing behavior. The pattern of activation of striatal cholinergic and PV interneurons 
by cortical and thalamic afferents, respectively, may have an important role in the 
suppression of unwanted motor activity. For example, as discussed above, cholinergic 
cells within the striatum receive a “copy” of corticothalamic projections conveying 
sensorimotor information to the cerebral cortex, therefore a decrease in cholinergic 
neuron number will inevitably decrease the integration of multimodal information within 
the striatum. We hypothesize that a decrease in integrative ability may create a 
“disconnect” that facilitates tic behavior. This is dramatically demonstrated by 
neurosurgical experiments in which patients with intractable TS found partial relief from 
their symptoms after lesions of the intralaminar thalamic nuclei, or, more recently, when 
these nuclei were implanted with deep brain stimulation (DBS) electrodes [203]. As 
discussed above, the decrease in inhibitory and cholinergic striatal interneurons is likely 
to be attributable to a loss of cells rather than a downregulation in levels of specific 
transcripts or proteins.  Potential causes of the striatal interneuron loss include 
developmental misspecification of neurons, or toxic, degenerative, and inflammatory 




Inhibitory interneurons are generated within the basal telencephalon during embryonic 
development. This region encompasses three ganglionic eminences, the medial, lateral, 
and caudal eminence (MGE, LGE, and CGE, respectively). Cholinergic neurons are 
generated in the preoptic area, a more medial and caudal region adjacent to the MGE. 
Neurons generated in these ventral regions migrate widely to the cerebral cortex and 
basal ganglia, in addition to the olfactory bulbs, amygdala, and hippocampus to reach 
their final destinations by the first postnatal week in rodents [1, 204, 205]. In humans, a 
portion of the cortical GABAergic interneurons might have a dorsal cortical origin, in 
addition to the common derivation from the basal telencephalon found in lower 
mammalian species [206]. 
 
Genetic programs directed by a series of divergent homeobox genes, including Nkx2.1, 
Dlx1,2,5,6, Gbx1,2 and Lhx6 control the specification, differentiation and migration of 
GABAergic neurons [207]. Ventral GABAergic fate is also instructed in part by the basic 
helix-loop-helix gene Mash1 (Long et al., 2009). This cascade is induced early in 
embryogenesis in ventral regions of the telencephalon by Sonic hedgehog (Shh), a 
secreted morphogen emanating from the notochord [208]. The homeobox gene Nkx2.1, 
the earliest gene required for interneuron specification, is an immediate downstream 
target of Shh signaling in the prospective MGE [209]. Nkx2.1 is an essential fate 
determinant, supported by the findings showing that mice lacking Nkx2.1 do not form 
the MGE or later the globus pallidus, lack basal forebrain cholinergic neurons, and have 
reduced numbers of cortical GABAergic cells, including PV and SST neurons, that 
 54 
migrate from the MGE into the cortex. Interestingly, haploinsufficiency of Nkx2.1 (also 
called TTF1) in humans has been reported in association with a dystonic movement 
disorder [210]. Dlx genes, which largely serve as ventral inhibitory interneuron 
progenitors, are downstream of Nkx2.1, expressed widely within both the LGE and the 
MGE, and are essential for several aspects of interneuron and subpallial development. 
For example, Dlx5 and Dlx6 are required for the migration, maturation, and function of 
PV cortical interneurons [211], whereas Dlx1 is required for CR, SST, and NPY-positive 
interneurons [212]. All Dlx mutants have disrupted striatal differentiation and epilepsy 
(Long et al., 2009). In the absence of Dlx1&2, there is an over-expression of Mash1, 
suggesting its compensatory ability in restoring aspects of striatal development and the 
potential for Mash1 signaling to be parallel, overlapping and/or redundant to that of Dlx. 
The analyses of triple mutant mouse (Dlx1&2-/-;Mash1-/-) reveal their combined function 
in promoting complete striatal differentiation and establishing distinct dorsoventral 
domains (Long et al., 2009). It is interesting to note that there has been some debate 
around the initiation of Dlx/Mash1 signaling in the ventral telencephalon, and whether or 
not Shh is truly the triggering molecule for their signaling cascade. This debate stems in 
part from evidence revealing that while Fgf8 hypomorphs show a complete loss of both 
Nkx2.1 and Shh expression, Dlx expression persists (Storm et al., 2006). Further work 
untethering the complexities of these dynamic signaling pathways and their control over 
whole regional development is necessary to further define disorders compromising the 
basal ganglia, like TS. 
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While Nkx2.1 and Dlx genes mostly control MGE and cortical interneuron development, 
the homeobox genes Gsh1 and Gsh2 are required for the development of striatal 
interneurons by specifying LGE identity [213, 214]. Accordingly, Gsh1 and Gsh2 double 
mutant mice have severe hypoplasia of the striatum. In addition, Gsh genes are 
required for the development of olfactory bulb interneurons and telencephalic 
dopaminergic neurons [214]. In contrast, the LIM-homeobox gene Lhx8 is required for 
the development of cholinergic interneurons; Lhx8 mutants lack the nucleus basalis, a 
major source of the cholinergic input to the cerebral cortex, and exhibit reduced number 
of cholinergic neurons in several other areas of the subcortical telencephalon including 
the caudate-putamen, medial septal nucleus, nucleus of the diagonal band and 
magnocellular preoptic nucleus [171]. Interestingly, Lhx8 expression is reduced in the 
basal ganglia of TS individuals (see section 2.4), suggesting a possible developmental 
origin for the cholinergic defects. 
 
Degenerative and neuroinflammatory conditions  
The role of neuroinflammation in TS is not fully understood (see also Chapters 9 and 
14). In the normal brain, in addition to contemporary immune infiltration there are 
resident macrophages that enter the brain during embryonic development, and remain 
in a resting form until activated during infection or inflammation events [215-217] (for 
review see Engelhardt and Coisne, 2011; Saijo and Glass, 2011). Immune cells may 
also play a critical role in cell clearance and synaptic pruning during normal brain 
development [218]. Prenatal exposure to pathogens, and the resulting maternal immune 
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activation (MIA) during pregnancy, has been linked to increased risk for ASD and 
schizophrenia [219, 220]. It is unknown if in utero infections increase the risk of 
developing TS.  
 
In TS there is some evidence that the immune system can trigger an autoimmune 
reaction involving the basal ganglia, a condition called pediatric autoimmune 
neuropsychiatric disorders associated with streptococcal infection (PANDAS). The 
PANDAS traditionally stemmed from the hypothesis that an infection with Group A β-
hemolytic streptococcus (GABHS) [63, 221] can trigger TS in childhood  (for a review of 
the autoimmune hypothesis of TS, see Chapter 15). In support for such a hypothesis, 
TS individuals have displayed indices of immune activation, including increased anti-
neuronal and anti-nuclear antibodies [51, 222], decreased regulatory T cells [58], 
increased IL-12 and TNFα serum levels, that were also found to positively correlate with 
tic severity [57, 223] as well as increased IL-2 and monocyte chemotactic factor -1 
(MCP-1), a marker of chronic inflammation, in brain tissue [224]. These findings, 
however, have not always been replicated and remain controversial. Furthermore, there 
was a striking increase in the number of activated B-lymphocytes among a group of 
unselected adult patients with TS compared with healthy subjects [225]. Finally, there is 
a significant increase in maternal self-reported history of autoimmune disorders in 
TS/OCD, and in a subset of PANDAS subjects, compared to the general population 
[221]; and allergic comorbid symptoms were described to be significantly stronger in 
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patients with a dual diagnosis of tic disorders and ADHD, than in patients suffering from 
only one of those disorders [226]. 
 
Brain transcriptome analysis revealed that expression of genes involved in several 
immune system pathways are upregulated in TS subjects, including genes involved in 
inflammatory response and immune cell trafficking [10]. Some of the immune pathway-
associated genes found to be upregulated in the brain of TS individuals have previously 
been found to be upregulated in the blood of these patients [227, 228], suggesting that 
changes in lymphocytes as well as myeloid-derived cells 
(monocytes/macrophages/microglia) may occur in this disorder. Interestingly, 
upregulation of several immunoglobulin genes were detected in the brain transcriptome 
of TS individuals, which agrees with evidence of abnormal oligoclonal bands of IgG in 
the cerebrospinal fluid of TS patients, suggestive of increased intrathecal IgG 
production [229]. 
 
How might these findings interface with the neuropathological findings? It is possible 
that the loss of interneurons in TS may be secondary to neuroinflammation. If aberrant 
immune cell access to the brain is causal in TS, the noted decreases in PV+ and ChAT+ 
interneurons may be resulting from immune cell reactivity; however, such auto-immune–
mediated cell loss is in contrast with the absence of increased loss of interneurons with 
age. Alternatively, the immune system may be acting in a stereotyped way, following 
some causal trigger that leads to a cascade of cues and ultimately to increased immune 
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cell adhesion and infiltration into the striatum. Moving forward, the rapid onset of TS 
symptoms following immunological challenge in PANDAS cases provides an interesting 
subset of subjects in which to further explore the role of the immune system in TS. 
 
Therapeutic implications 
Discovering the neurophysiological substrate for tics and other symptoms of TS is of 
paramount importance for treatment. Even in the case of developmental alterations, 
where the causes are likely to be remote, there is still hope that we could find 
treatments that compensate for brain circuitry dysregulation. In the case of cell losses or 
dysfunctions induced by immunological alterations, potential treatments could be tried 
similar to those employed in autoimmune disorders of the CNS. Finally, comparable to 
what has been successfully tried in other basal ganglia disorders such as Parkinson’s 
disease, neurotransmitter or cellular replacement therapy (locally delivered) represents 
a difficult but open area for therapeutics. It has been recently demonstrated in mouse 
models of seizures that transplantation of GABAergic interneuron precursors in the early 
postnatal mouse cortex results in diffuse cortical engraftment of exogenous GABAergic 
cells, and reversal of epileptic symptoms [230, 231]. 
 
 
BOX 1. Key points 
• In TS there are decreases in parvalbumin+ GABAergic  interneurons and 
cholinergic interneurons in the CD and PT. 
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• There is also loss of the normal distribution (highest in associative regions, 
intermediate in sensorimotor, and lowest in limbic regions) of cholinergic 
interneurons. 
• There are no evident changes in ChAT distribution in striosomes vs matrix. 
• There may also be changes in another interneuron population, the NOS-
containing interneurons. 
 
BOX 2. Questions for future research 
• Developing mice with selective PV or cholinergic neuron inactivation or loss in 
the basal ganglia may allow studying direct and indirect behavioral and 
physiological consequences of this manipulation and eventually yield insights into 
the roles of these interneurons in the basal ganglia and in TS.  
• Regarding the neuropathological changes that have been noted based on post-
mortem tissue assays (western blot, qPCR, RNAseq), homogenization of tissue 
was done to isolate the RNA or protein. Future analysis of the candidate targets, 
e.g., immune system related genes, will help to determine if there are specific 
cells or regions where these markers are differentially expressed. Studying 
spatial gene expression in postmortem brain tissue slices was developed as a 
powerful tool to understand the impact and interconnections of transcriptional 
changes within and/or between brain regions. This strategy enables to study the 
transcriptome on a single cell level without losing the valuable information of 
exact location. This will ultimately reveal brain circuitry that is abnormal in this disorder. 
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• Three-dimensional cell structures, called organoids, enable to study early 
timepoints of human development in vitro. Using TS patient derived iPSCs to 
generate organoids mimicking the cortico-striatal circuitry will be crucial to 
understand the underlying cause of TS. 
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Top IPA Biofunctions p-Value # Molecules 
Nervous System 
Development & Function 
neurotransmission 1.65E-23 40 
synaptic transmission 1.22E-21 35 
Behavior 
behavior 2.70E-22 57 
learning 3.08E-19 34 
anxiety 2.11E-18 35 
Neurological Disease 
Schizophrenia 1.22E-15 36 
Psychosis 2.25E-12 14 
Top IPA Canonical Pathways  -log(p-value) 
cAMP-mediated signaling 4.96E00 
G-Protein Coupled Receptor Signaling 4.95E00 
GABA Receptor Signaling 3.65E00 
Top IPA Upstream 
Regulators   p-value of overlap 
NGF growth factor 1.01E-12 
HTT transcription regulator 9.19E-12 
BDNF growth factor 4.93E-10 
    
UP-REGULATED 
Top IPA Biofunctions p-Value # Molecules 
Cell-To-Cell Signaling & 
Interaction 
activation of cells 9.18E-77 193 
activation of blood cells 1.48E-74 166 
Hematological System 
Development & Function 
quantity of blood cells 1.71E-74 199 
quantity of leukocytes 6.22E-71 182 
Immune Cell Trafficking leukocyte migration 7.85E-67 170 
Inflammatory Response 
activation of leukocytes 3.02E-68 150 
inflammatory response 5.27E-61 148 
IPA Canonical Pathways  -log(p-value) 
Granulocyte Adhesion and Diapedesis 2.13E01 
T Helper Cell Differentiation 2.03E01 
Dendritic Cell Maturation 1.8E01 
IPA Upstream Regulators p-value of overlap 
lipopolysaccharide chemical drug 3.14E-87 
IFNG cytokine 1.71E-78 
TNF cytokine 1.32E-65 
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Table 2. Hand-curated subset of differentially expressed genes.  Genes are listed 
under the category they represent, along with log2 fold change (log2 FC) and FDR 
corrected p-values (FDR) 
Cholinergic FC FDR 
CHAT choline O-acetyltransferase -2.31 1.39E-07 
CHRM2 cholinergic receptor, muscarinic 2 -1.99 4.32E-04 
SLC18A3 solute carrier family 18 (vesicular acetylcholine), member 3 -2.17 4.04E-05 
SLC5A7 
CHT1; solute carrier family 5 (choline transporter), member 
7 
-2.55 6.65E-08 
LHX8 LIM homeobox 8 -1.90 1.39E-03 
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 -1.91 1.17E-03 
GABAergic log2 FC FDR 
GAD1 glutamate decarboxylase 1 (brain, 67kDa) -1.64 1.21E-02 
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 -1.47 2.31E-02 
GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 -1.96 5.85E-04 
GABRG2 gamma-aminobutyric acid (GABA) A receptor, gamma 2 -1.50 2.61E-02 
GABRQ gamma-aminobutyric acid (GABA) A receptor, theta -1.82 1.11E-02 
NOS1 nitric oxide synthase 1 (neuronal) -1.58 6.40E-03 
NPY neuropeptide Y -1.66 8.15E-03 
NPY2R neuropeptide Y receptor Y2 -2.81 2.33E-04 
SST somatostatin -1.59 4.42E-03 
Dopaminergic log2 FC FDR 
DRD1 dopamine receptor D1 -1.50 3.20E-02 










SHH patterns human stem cells towards ventral forebrain fates 
 
Introduction: modeling of CNS development and disease in 
vivo and in vitro 
Development of the human central nervous system (CNS) is a complex series of sequential 
molecular events that guide cellular proliferation, differentiation, and migratory patterns to build 
the organization of what are the most advanced neural circuits in the animal kingdom. These 
processes generate a vast cellular diversity integrated into networks that ultimately produce 
higher-order human functions, from cognition and motor coordination to consciousness.  
  
The inherent complexity of the human CNS has historically complicated scientists’ ability to 
model and understand all of its parts, thereby making the study of developmental and 
degenerative abnormalities equally challenging. While animal models have long served as tools 
to uncover human neurobiology, their limitations have continued to emphasize the need for a 
reliable human model system. For instance, the anatomical and cellular differences across 
species impact the degree to which healthy and disease pathophysiology can be convincingly 
captured. Due to the essential role that the basal ganglia plays in both learning [232, 233] and 
motor processes [234], as well as its implication in a broad range of neuropsychiatric disorders, 
this subpallial region and its circuitry has been investigated in many animal models, from 
rodents to primates. While general cortico-basal ganglia regional architecture is maintained 
across rodents and humans, the globus pallidus pars interna, termed entopeduncular nucleus in 
rodents, and the frontal cortex are both comparatively immature structures in rodents [235]. 
Basal ganglia output also varies across humans and rodents, with extensive output to the 
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thalamus versus midbrain and brainstem regions, respectively [236]. Further, certain cell types, 
such as outer radial glia of the dorsal telencephalon, that are essential to human cortical 
development are substantially lacking in rodents [237]. Additionally, disease modeling in 
animals often requires genetic engineering to mimic human dysfunction that does not naturally 
occur, and leads to animal behaviors that are sometimes difficult to characterize in the context 
of human phenotypes. Higher order processing achieved by the human brain also suggests the 
possibility for equally complex and intricate abnormalities, and yet another reason why a 
human-specific model system has become an empirical necessity. 
  
Human induced pluripotent stem cell (iPSC)-derived organoids are tridimensional multilayered 
aggregates with the intrinsic capability to capture human embryonic development. For this 
reason, organoids present a tremendous opportunity to model both human development and 
disease to further not only our biological understanding but also our clinically relevant 
investigations, from diagnosis to therapeutics. Human iPSC technology came during a time of 
great ethical distress over the use of embryonic stem cells, which gained empirical traction after 
the use of murine pluripotent cell lines [238, 239]. Instead of sacrificing a human embryo, 
scientists found that pluripotent stem cells could be generated from the initial harvest of a simple 
adult human fibroblast. The exposure of fibroblasts to a cocktail of reprogramming factors 
reverts their development back to pluripotency, from which point the cells can be differentiated 
into any cell of the human body [240, 241]. Organoids take the lead as the model system with 
the greatest potential to resemble the complexity of human development, and the iPSCs from 
which these aggregates are derived endow the system with the ability to develop into all 3 germ 
layers – the endoderm, mesoderm or ectoderm. For the scope of this review, however, we will 
focus on ectoderm-derived neural organoids. Another defining feature of the organoid system 
that elevates its potential beyond animal models is its subject-specific design. From a simple 
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non-invasive skin biopsy [241], or more recently urine [242, 243] or blood samples [244-246], 
the patient’s cells are reprogrammed to iPSCs and cultured to become neural organoids while 
maintaining the patient’s specific genetic background. This subject-specific nature carries the 
potential to reveal brain cytoarchitecture that resembles that of the individual from which the 
cells originally came. This opens another door of possibility, especially when considering 
disease modeling and medical treatment plans, paving a way towards precision medicine. An 
additional technical benefit is that, once reprogrammed, the iPSCs can be cultured into 
perpetuity, essentially creating an immortal system that can generate an unlimited reserve of 
cells.  
 
At the same time, there are limitations of the organoid system to consider, as well. Among them, 
the struggle of organoid reproducibility has sparked substantial efforts towards protocol 
optimization; similarly, variability of cellular expression can be observed across preparations – 
both realities that raise questions about system efficiency. For additional detailed information on 
these limitations, please refer to the cited reviews [247, 248]. While organoid cultures can be 
maintained long-term for several months, achieving widespread organoid health for the same 
potential lifespan has been equally challenging. Further, some critical complexities of 
neurodevelopment have yet to be distinguished in the organoid cultures – including, but not 
limited to, vascularization of the tissue, and organization of all six human cortical layers, which is 
typically guided by the meninges (for reviews on these limitations, REF [249-252]) Given that 
the organoids capture embryonic-stage development best, deciphering whether organoids are 
applicable to both neurodevelopmental and neurodegenerative disorders is an ongoing 
investigation. Although the organoid system is still young and developing, it has vast potential 
and its methodology is ever-evolving. 
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Culturing human neural organoids begins first with the single layered iPSCs. The cells are 
placed in a physical environment that fosters their assembly into a tridimensional aggregate. 
Guided by a set of morphogens, the aggregates become embryoid bodies – named for their 
ability to become any of the 3 germ layers. However, with further culturing, these aggregates 
can be pushed to adopt a neural fate and express a diverse array of progenitors mimicking early 
regional patterning of brain tissue [253]. Once the regional identities are specified, withdrawal of 
mitotic factors from the media fosters post-mitotic differentiation of various cell types that reside 
within said regions. These aggregates are self-organizing and their morphological growth occurs 
spontaneously. However, unmodified organoid patterning only goes so far. Studies have found 
that neural aggregates inherently adopt a cortical (dorsoanterior) telencephalic fate by default 
[11-14], similar to the developing cerebral cortex. We can capture a broader range of human 
anatomy, however, by introducing critical factors that endogenously pattern the CNS into 
various regions.  
 
SHH signaling during embryogenesis 
The basal ganglia arise from the ventral telencephalon, an anterior extension of ventral 
neuraxis, which is patterned by the Sonic Hedgehog (SHH) signaling pathway In normal 
vertebrate development. This dynamic protein serves a multitude of functions in a context-
dependent manner, both as a mitogen to promote cellular proliferation, and a morphogen to 
direct cellular and regional specification towards ventral fates [254-257]. Embryological 
investigation has exposed many of the multifaceted roles that SHH plays in development, 
adding insight both empirically and clinically due to the disorders observed with deficits in SHH 
expression [255, 258-260]. The most notable role for this dynamic morphogen is in neural 
patterning of the central nervous system.   
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Before we focus on the varying ways that SHH has been used to pattern stem cells, the 
command that this ligand has on instructing neural diversity and cellular organization must first 
be understood. One of the first SHH-expressing tissues during mammalian embryogenesis is 
the notochord, which begins its developmental influence in early neural plate stages and 
crescendos upon neural tube formation [FIGURE 1.2] [261-263]. SHH emanates from the 
notochord, and its role as a chief ventralizing signal has been originally discovered from 
transplantation experiments in chick embryos [264-266] and in vitro experiments with neural 
plate tissue explants [262, 263, 267]; these works were further complemented by genetic 
experimentation for both gain- [267, 268] and loss-of-function [258] SHH signaling. The 
notochord has immediate contact with the floor plate at the ventral midline of the neural tube, 
and induces these nearby cells to express SHH [FIGURE 1.2B] [269]. The capacity of SHH to 
program a variety of cellular identities is explicated in a graded fashion, as indicated by in vitro 
studies [FIGURE 1.2B] [270]. The cells of the floor plate secrete SHH and establish a 
concentration gradient within the CNS with the most elevated protein levels found ventrally; the 
degree to which different cell types emerge, therefore, is concentration-dependent. There is a 
unique ‘release and response’ duality of the neural tube that is essential for determining the 
positioning of cell types along the main coordinates of the neuraxis, whereby a proportion of 
neural tube cells, found ventrally, express and secrete SHH, while another large portion of 
neural tube cells respond to the ligand in a concentration-dependent fashion. The SHH 
concentration gradient ultimately governs the patterning of the central nervous system along the 
dorsoventral domains. SHH has antagonistic interactions with the dorsally-expressed bone 
morphogenic proteins (BMP) and WNT signaling proteins which will fully define the limits of the 
range of each domain. Herein lies the initial guide to the central nervous system’s rise to cellular 
diversity.  
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Cell types requiring SHH signaling in vertebrate development 
and their role in diseases of the CNS 
Along the rostrocaudal axis, SHH, in conjunction with other morphogens, induces cell types at in 
ventral domains at various levels in the forebrain, midbrain, hindbrain and spinal cord [FIGURE 
1.2A,C]. In the forebrain, SHH promotes the differentiation of the ventral telencephalic 
ganglionic eminences, which contribute to adult basal ganglia formation [271]. In addition, the 
ventral telencephalic ganglionic eminences are the site of origin of essentially all telencephalic 
inhibitory interneurons [272]. Therefore, SHH is essential for kick-starting the cascade of 
signaling that leads to the development of many classes of inhibitory interneurons that 
eventually populate the forebrain, modulating excitatory neurotransmission and are integral 
components of an optimally functioning cortico-basal ganglia circuitry that directs motor 
coordination and cognition. Additionally, SHH governs dopaminergic and serotonergic neuronal 
fates in the midbrain and hindbrain regions, essential for motor and emotional control, 
respectively [264, 273-275]. Ye and colleagues showed that achieving such neuronal diversity is 
directed by the distinct combination of molecular positional cues, assembled in an informational 
“grid” system of morphogens [275-277].  The developmental grid system of morphogens and 
fate determinants, first described by Wolpert [276] and further defined by Rubenstein and 
colleagues [277], organizes regional neural patterning and cell fate essentially creating a 
topography. Extracellular molecules determine the grid and serve as signaling centers during 
development. As cells mature, cell type specificity is acquired based on the cells’ precise 
location within this developmental grid. Ye et al further investigated this grid system concept in 
rat ventral midbrain and hindbrain explants [275]. By manipulating exposure to SHH and FGF8, 
blocking functionality of the morphogens, and controlling timing of morphogen exposure, Ye and 
colleagues showed that dopaminergic induction and neuronal commitment throughout the 
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midbrain and forebrain required signaling from both SHH and FGF8. More caudally, introduction 
of FGF4 signaling pre-patterns the rostral hindbrain, such that subsequent signaling of FGF8 
and SHH pushes progenitors to adopt a serotonergic fate instead of dopaminergic [275]. 
Extending caudally from the hindbrain to the spinal cord, SHH promotes the differentiation of 
motor neurons and ventral interneurons. Later in development, SHH plays an essential role in 
oligodendrocyte development at many levels of the neuraxis [278]. These cell types make 
myelin which is critical for the speed of neural signaling and integration of sensory information 
[270, 279, 280].  
  
Understanding the neurodevelopment of these important cellular lineages provides the 
necessary foundation from which we can decipher perturbations that yield neurological 
disorders, of both a neurodevelopmental and neurodegenerative nature. For instance, altered 
development of dopamine neurons, originating in the substantia nigra of the midbrain and 
projecting to the basal ganglia of the ventral forebrain, has been linked to both movement and 
neuropsychiatric disorders, from Tourette Syndrome [281, 282] to Schizophrenia [283-285]. 
Additionally, dysfunction and fluctuations in serotonergic neuron numbers, originating in the 
hindbrain but whose axonal projections innervate areas throughout the entire brain, are directly 
implicated in many neuropsychiatric disorders such as anxiety and depression [286-288]. In the 
forebrain, abnormal development of the striatum in the basal ganglia contributes to other 
movement and psychiatric disorders, from Huntington’s Disease to Obsessive Compulsive 
Disorder (OCD).   
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Elucidating the SHH signaling pathway paves the way for 
application in in vitro patterning 
The fundamental role of SHH and other morphogens, revealed by gain-of-function and loss-of-
function studies, has paved the way for scientists to try to identify these complex processes in 
human models [254, 289, 290]. Pioneering genetic studies in Drosophila identified several key 
genes that are integral components of SHH signaling [291], most notably Patched, 
Smoothened, and three separate Gli genes (cubitus interruptus genes in Drosophila). Patched 
(ptc) and Smoothened (smo) are both transmembrane protein receptors, but mediate SHH 
signaling in opposing ways, in that ptc inhibits SHH signaling while smo activates it [292, 293]. 
In the absence of SHH, ptc binds smo and constitutively inactivates it, preventing signaling of 
the pathway. However, in the presence of SHH, the ligand binds ptc, which alters the receptor’s 
conformation; ptc then becomes physically untethered from smo, relieving its inhibition such that 
the SHH pathway can become active [294] [FIGURE 2.2]. Further examination of ptc and smo 
in vertebrates has suggested their similarly important roles in mediating SHH signaling to 
pattern the neural tube [292, 293]. 
 
As will be discussed in the next section, the SHH signaling pathway has been exploited as a 
vital component of many novel human in vitro strategies to uncover the neurobiology of 
developmental disorders and to discover novel therapeutic technology. The remainder of this 
review will discuss how the community has utilized SHH as a tool to promote neuronal 
differentiation into specific neuron types and regional development, and the biological and 
clinical applications of these distinct methodologies. We will briefly discuss the use of SHH in 
various monolayer stem cell preparations and their limitations before discussing its use and 
potential in the iPSC-derived organoid system. 
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The use of SHH in in vitro disease modeling  
To explore a potential cellular repair for Parkinson’s disease [295]. Kriks and colleagues used 
joint molecular activation of SHH and canonical WNT signaling to enhance specification of 
human embryonic stem cells (hESCs) towards a dopaminergic neuron fate. They achieved 
engraftable hESC-derived midbrain dopaminergic neurons that thrived long-term in the striatum 
of three different Parkinsonian animal model systems including 6-hydroxy-dopamine-ablated 
mice and rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned rhesus 
monkeys. Although the behavioral recovery was limited, the survival span of the graft was 1 
month, and led to robustly developed fibers positive for tyrosine hydroxylase, an enzyme 
required for dopamine synthesis.  
 
Another study revealed successful generation of GABAergic medium spiny neurons (MSN) from 
hESCs exposed solely to SHH treatment, and investigated the potential for cell therapy as a 
treatment for Huntington’s Disease [296]. Ma and colleagues found that treatment of hESCs 
with a specific concentration of SHH was sufficient to foster lateral ganglionic eminence (LGE)-
like development in monolayer neuronal cultures and ultimately MSN development after 
extended culture. Beyond gene expression, the SHH-treated hESC cultures produced the 
appropriate striatal MSN morphology, sprouting dendrites with spines, and the differentiated 
neurons displayed functional properties in the form of spontaneous synaptic activity as well as 
action potentials subsequent to current injection. Transplantation of these LGE-like progenitors 
into mice with lesioned striatal tissue confirmed the progenitors’ ability to mature and 
differentiate into GABAergic DARPP32-positive neurons, with concomitant recovery of volume 
loss and cellular concentration of the lesioned striatum as early as four months-post-transplant.  
 
 72 
While Parkinsonian symptoms can be ameliorated by sufficient replenishment of dopamine 
stores, the complexity of circuitry restoration remains a barrier for developing Huntington’s 
Disease treatments. Long range projections, characteristic of medium spiny neurons, are 
required to innervate various target regions of both the basal ganglia and cerebral cortex to 
regulate the dynamic motor circuits. Both distance and continued cellular access serve as 
considerable obstacles that the in vitro-generated neurons have yet to overcome. That being 
said, these findings convey the powerful control SHH has alone to pattern developing neurons 
to a quasi-mature and functional extent in an animal model. 
 
Another study found that prolonged long-term exposure of iPSCs to SHH could ultimately yield 
motor neurons able to form neuromuscular connections upon co-culturing with myotubes [297]. 
Du and colleagues used iPSC-derived SHH-induced motor neurons to model disorders plaguing 
specifically motor neuron populations, including spinal muscular atrophy (SMA) and 
amyotrophic lateral sclerosis (ALS). Du et al capitalized on the patient-specific nature of the 
iPSC technology and compared patient-derived motor neurons to healthy controls. The 
expression of the survival motor neuron (SMN) gene was, as expected, decreased in 
differentiated motor neurons cultured from hiPSCS derived from SMA as opposed to non-SMA 
control individuals. Further, differentiated motor neurons from ALS individuals carrying the D90A 
mutation in the superoxide dismutase gene (SOD1), revealed a downregulation of NEFL gene 
expression, encoding for the light polypeptide neurofilament protein, consistent with this 
particular ALS mutation. These findings highlight the ability of SHH to direct the correct 
generation of cell types equipped with appropriate endogenous machinery, such that this in vitro 
approach was capable of recapitulating disease phenotypes.  
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The potential use of the SHH agonist for discovery and application is further exemplified by yet 
another recent study utilizing SHH to direct the differentiation of functional serotonin neurons of 
the raphe nucleus [298]. Using both hESCs and hiPSCs, Lu et al. showed that transient 
exposure to SHH was sufficient to bias hindbrain progenitors towards a serotonin fate. SHH 
signaling, along with WNT activation, were the essential modulators used to enrich the cultures 
towards tryptophan hydroxylase-positive, electrophysiologically functional serotonin neurons.  
 
Important to note, while both motor neuron [297] and serotonergic neuron [298] generation were 
obtained under the influence of similar morphogenic cocktails, achieving these distinct neuronal 
populations was possible by adjusting timing and concentration of these morphogens. For both 
preparations, it was imperative to first caudalize the cultures with WNT agonists to achieve a 
posterior fate, before ventralizing the system with SHH. While this is true for both motor and 







The motor neuron preparation also coupled the SHH treatment with retinoic acid to assist in 
ultimate differentiation, which was absent from the serotonergic preparations. Similar to the 
endogenous human system, interactions among these differing factors play significant roles in 
the developmental trajectory and ultimate differentiation of these neuronal populations.  
 
After ascertaining the appropriate gene expression patterns consistent with serotonin neurons 
[298], the cultures were utilized for pharmacological screening to reveal the potential of the in 
vitro methodology as a system to test drug candidates for disease treatment. Two classes of 
serotonin-targeting drugs were tested, including activators of serotonin release and selective 
serotonin reuptake inhibitors. The treatment of the hiPSC-derived hindbrain serotonin neurons 
with either class of drug resulted in increased serotonin concentration in both a dose- and time-
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dependent manner, validating the known pharmacology of the drugs. Therefore, the 
differentiated serotonin neurons present a potential experimental approach for examination of 
drug therapies for a number of neuropsychiatric disorders, including, but not limited to, a variety 
of eating, sleep and mood disorders. 
 
While these studies show the broad range of applications for SHH in in vitro systems, there are 
many limitations of the 2D system still to consider. The over-arching theme is that the 2D 
system’s does not closely recapitulate the physiological complexity and developmental biology 
of the human system. The 2D system cultivates homogeneous cellular populations, unlike in 
vivo physiology, and this biological simplicity significantly limits cellular interactions thereby 
disrupting the overall development of the cells. The variety of functions that a single cell type 
possesses is a combined result of its environment, the cellular network it resides within and the 
other cell types with which it communicates. The impairment in cell-to-cell interactions which are 
inherent to a 2D system, coupled with excessive contact with extracellular matrix, result in 
biological deficiencies which are seen not only in these cells' morphologies and survival, but 
also their ability to differentiate. As discussed in the Lu et al study, many serotonin-expressing 
cells in the 2D system lack the cellular mechanics and equipment to function properly. As 
described in the Du et al study, motor neuron progenitors cultured in the 2D system have a 
short lifespan and limited differentiation potential, lasting a mere 2-5 passages only before 
losing their potency. These differentiation impairments, in addition to difficulties in replicability of 
the preparations, can also arise from the lack of cell-to-cell contacts and Notch signaling among 
precursors and daughter cells [299]. These limitations make the use of the cells for disease 
modeling, drug screening and cellular replacement unpredictable.  
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Furthermore, the aforementioned studies have had few or no follow-up investigations, which 
raises the question of additional complications in reproducibility, reliability and applicability of 
these systems. Important to note, serotonergic neuronal generation was followed up by 
additional characterization of the serotonergic neurons post-transplantation in the mouse brain 
[300]. While the transplanted neurons were found to project to various regions of the hindbrain, 
their projections were limited and not seen to reach the anterior regions of the brain. Thus, 
although this transplantation survival shows promise, future follow-up studies are necessary 
before the 2D model systems can be applied to human therapeutics. 
 
The potential of organoids to accurately capture the diversity of the endogenous cellular milieu 
comes from its ability to mimic the cytoarchitecture of the human brain by self-organizing into a 
multilayer aggregate where different cell types interact and signal to each other through close 
intercellular contacts [FIGURE 3.2]. For example, ventricular radial glial cells communicate via 
N-cadherin and Notch signaling [301] and outer radial glia through LIFR-STAT3 [302] and 
mTOR [303] signaling, all of which profoundly influence their differentiation. Additionally, unlike 
the 2D system, organoids can be cultured for months at a time and even up to a year, maturing 
into electrophysiologically functional and biologically robust neural aggregates. This improved 
differentiation and maturation allow the development of long-range projections after organoids 
transplantation in mice, overcoming an obstacle that was of great consideration for the 
aforementioned medium spiny neuron development [304, 305]. Indeed, Mansour et al were able 
to show subpallial innervations following cortical transplantation of organoids in mice, with 
axonal projections to not only the striatum but to rostral regions as well. Additionally, projections 
spanned both hemispheres, with evidence of projections crossing the corpus callosum [304]. 
These works provide support and promise for the future of the organoid system. The remainder 
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of this review will focus on the use and potential of SHH in the organoid system towards 
development and disease modeling. 
 
The future of In Vitro technology 
Scientists have continued to push the boundaries of empirical possibility, discovering strategies 
that more realistically render neural networks and neuronal circuitry. Beyond any previous in 
vitro system, organoids have better reproduced the range of cell phenotypes that reside in a 
specific brain region, and offer an assay to model the developmental interactions of two or more 
brain regions, recapitulating dynamic and complex migration patterns, regional crosstalk and 
brain circuitry. These single-region organoids or multi-region assembloids present remarkable 
new opportunities to examine circuit dysregulation and inhibitory/excitatory imbalances plaguing 
many neurodevelopmental disorders.  
 
The organoid system reproduces the embryonic-fetal window of development, a unique and 
essential time span that is difficult to thoroughly investigate in many other model systems [13, 
15]. Researchers have used these multilayered diverse cellular aggregates to grow various 
brain regions and model many diseases, from Autism Spectrum Disorder [18] to Rett Syndrome 
[306] and Timothy Syndrome [125]. Individually cultured dorsal and ventral forebrain regional 
organoids were fused to achieve whole forebrain-like organoids, complete with migrating DLX2+ 
inhibitory populations in the ventral-dorsal direction, mimicking in vivo neuronal behavior [16, 
125]; these experiments required the use of SHH agonists to stimulate development of the 
ventral forebrain and its migrating progenitors. With a recent influx of methods to foster ventral 
telencephalic-like organoids, the potential to study neurodevelopmental disorders affecting the 
basal ganglia, such as OCD and Tourette Syndrome, is perceivably high.  
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The union of independently generated regional organoids into assembloids achieves active 
cross-regional communication via processes such as cell migration; however, the cohesive 
nature of whole forebrain development and fluid transition of gene expression and cellular 
diversity is lost in assembloid strategies. As described earlier in this review, multi-axis neural 
patterning – dorso-ventral, medio-lateral, and anterio-posterior – is instructed by the SHH, WNT 
and BMP gradients endogenously established during neurogenesis [FIGURE 1.2B]. The 
gradient fosters a precise topographic map that specifies regional identity within the human 
brain. Cederquist et al. recognized that current organoid technologies lack such holistic 
topography, although it is an essential feature of neurodevelopment. To mimic in vivo spatial 
organization of the human forebrain and achieve distinct positional domains, Cederquist et al 
developed an inducible SHH-expressing hPSC line (iSHH) to initiate an inducible (rtTA-
dependent) SHH gradient at a single pole of an organoid [307]. To create what Cederquist and 
colleagues refer to as a SHH organizer, 1,000 iSHH cells were cultured independently to 
become a mini cellular aggregate, after which time a larger number of wild-type cells were 
added to assemble atop and fuse to the iSHH aggregate. The product created what the group 
refers to as a “chimeric spheroid”, with a much smaller ratio of iSHH cells to wild-type cells 
[307]. The organoid’s response to the resultant SHH protein product then becomes a function of 
distance: the farther away cells are from the SHH organizer, the weaker the SHH-induced gene 
expression, thereby creating a gradient effect within the organoid and constructing a neuraxis.  
 
The SHH organizer successfully produced four positional identities, dorsal, ventral, anterior and 
posterior [307]. Immunochemistry revealed the strong ventral expression of NKX2.1 in cells 
closest to the organizer, while those farthest away expressed the dorsal PAX6. Additionally, 
cells farthest from the organizer also expressed the anterior FOXG1 while those closest 
expressed the posterior OTX2. The distribution of SHH as its expression gradient traversed the 
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organoid achieved the major subdivisions of the human forebrain, including the neocortex and 
ganglionic eminences MGE and LGE, and even anterior hypothalamic development [307].  
 
The inducible system generated a single organoid representative of topographically ordered 
multiple cellular fates and regional identities. When comparing the 3D strategies currently 
available for neurodevelopment, the iSHH system has its advantages, as it more thoroughly 
captures the interconnectedness of the human forebrain. There are surely synchronous as well 
as sequential elements of neuro-pathway activation, the compound impact of which is essential 
for mimicking the remarkable complexities of neurodevelopment, and are likely missing from 
multi-organoid assembloid generation. A gradient-based system, as achieved with the SHH 
organizer, inches closer to in vivo conditions and is more capable of mimicking the dynamic 
cellular continuum achieved by the human forebrain. That is because morphogen’s 
concentrations inherently have differential ability to transcriptionally control gene expression, 
where precise concentrations either induce or silence gene expression and related cascades of 
signaling events, hence the complexity that gradients can establish.  Furthermore, gradient-
based organoid systems can be combined with multi-regional assembloid, where benefits to 
each are compounded, and may help construct the most appropriate systems to use to answer 
the empirical question in the end.  
 
The in vitro organoid system provides, at least in principle, a source for investigation of a variety 
of developmental periods, with the potential to model therapeutic approaches, including 
modulation of gene expression, gene editing, and drug design. The tridimensional design offers 
a strategy that can enhance the empirical study of Parkinson’s and Huntington’s diseases 
mentioned previously, as well as a wide range of other neuropsychiatric disorders. Using either 
the assembloid or gradient approach, the development of dopaminergic projections from the 
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human substantia nigra to the striatum can be investigated and their abnormalities 
characterized in a Parkinsonian organoid model. Long range projections of medium spiny 
neurons from the striatum to the other regions of the basal ganglia can be modeled and their 
functionality tested in a Huntington’s organoid model. Tourette Syndrome and OCD can be 
modeled by observing the development of the basal ganglia, and cortico-basal ganglia circuitry 
can be tracked in these diseases as well. These are only some of the possible applications of 
this system, but there are many exciting doors to be opened with this technology to advance our 























Figure 1.2. Schematic of neural tube formation and cerebral regional 
identity. (A) Regional definition of the neural plate with rostrocaudal axes and its 
contact with the SHH-releasing notochord. (B) Formation of the neural tube and its 
contact with the SHH-releaseing notochord. Doroventral and rostrocaudal axes 
are defined with corresponding critical morphogenetic gradients: Dorsal BMP; 
Ventral SHH; Rostral Noggin; Caudal WNT) (C) Development of the embryonic 























































Figure 2.2: SHH signaling pathway. (A) SHH pathway in the absence of SHH ligand. 
PTC inhibits SMO activity, thereby inhibiting its ability to positively influence transcription 
(dashed lines). Nuclear transcription of downstream SHH targets is stopped. (B) SHH 
pathway in the presence of SHH ligand. SHH binds PTC, lifting its inhibition on SMO 
(dashed lines), thereby allowing SMO to positively influence transcription. Nuclear 























A word about GLI proteins and SHH signaling 
The following section is on GLI proteins and their significance in SHH signaling within 
the developing forebrain. This section is not part of the official review in this chapter; 
however, GLI proteins and their role in patterning dorsal and ventral regions of the 
telencephalon are an essential component of my thesis work. Therefore, the following 
section is necessary for understanding the trajectory of this thesis. 


Figure 3.2: Human iPSC-derived organoid. iPSC-derived organoid was 
transduced at 7 months of age with SYN-GFP to illuminate neuron-specific 
development. Imaging was obtained by two-photon microscopy to show longevity 
and network complexity within these 3D aggregates. 
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Continued study of SHH signaling in vitro could yield impactful advances both 
scientifically and clinically. The temporal and spatial precision with which SHH helps 
specify these many cell types remains unclear, and the dynamic processes still leave 
much to be appreciated. The mechanistic features of the powerful SHH signaling must 
not be overlooked. Signal transduction of the SHH signaling pathway is a primary leader 
of cellular commitment and network organization, and is a possible source of 
developmental abnormality. 
 
In addition to the transmembrane patched and smoothened proteins, key players in SHH 
signaling are the Gli genes (Gli family zinc finger genes), producing the transcription 
factors Gli1, Gli2 and Gli3 [294, 308]. Genetic studies in mice have shown Gli1 and Gli2 
to mainly promote transcription after SHH signaling, while Gli3 functions mainly to repress 
transcription [309]. Gli1 is not proteolytically cleaved, and therefore does not exhibit 
repressor activity; however, both the Gli2 and Gli3 transcription factors have the capability 
to function as activator or repressor, and in fact SHH signaling inhibits the proteolytic 
processing of Gli2 and Gli3, suppressing their repressor activities [310-312]. Given their 
functions, the Gli proteins occupy distinct regions of the neural tube. Gli1 [FIGURE 4.2] 
is expressed ventrally. In response to SHH signaling, Gli1 increases transcription for 
downstream targets, such as NKX2.1, thereby ultimately facilitating ventral cell type 
specification. On the other hand, Gli2 and Gli3 are found dorsally [FIGURE 4.2]. Gli2/Gli3 
are proteolytically processed to become repressors of the SHH pathway; once processed, 
they antagonize SHH signaling to instead promote dorsal forebrain patterning. The 
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categorization of these proteins into activators and repressors stems from long-standing 
genetic research on mutant mice [259, 313, 314]. In Gli3-/- mutant embryos, the cortical 
plate, denoted by EMX1/2 protein expression, is reduced, due to disruption in dorsal 
telencephalic development; this results in a significantly smaller cortex, olfactory bulb and 
hippocampus in the mutant embryos. And while dorsal territory shrinks in these mice, the 
ventral territory was found to expand, indicated by significant increases in ventral 
progenitor gene expression, including NKX2.1 and DLX2 [259]. Additional studies have 
shown that transfection of embryos with Gli3 in its repressor form stunted development 
of both ventral progenitors and motor neurons, and promoted expansion of dorsal gene 
expression within the ventral neural tube [315]. This research indicates that Gli3 has dual 
functionality, to both promote dorsal specification and also inhibit ventral commitment; 
whether these processes stem from two distinct mechanisms remains unclear. More 
importantly, however, these findings suggest a predominantly cell-autonomous response 
to Gli signaling that can easily translate to a disruption of dorsoventral patterning of the 
neuraxis.  
 
Interesting to note, while all three Gli proteins influence neural tube patterning, loss of 
Gli2 has been found to have the most fatal developmental consequences. Gli1 knock-out 
mice proceed to full term, are viable and fertile [316]; and although Gli3 loss-of-function 
mutations yield phenotypes mimicking overexpression of SHH signaling [317], for 
example, polydactyly [316], Gli3 mutants are viable nonetheless. However, Gli2 
homozygous null mice are not viable and display dramatic neural tube defects [318, 319]. 
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Furthermore, Gli2 – not Gli1 – has been genetically shown to be required for floor plate 
formation within the neural tube [318-320]. Loss of function Gli2 mutations leads to 
holoprosencephaly, including most notably deficient medial forebrain development and 
altered ventral neurospecification [321]. Interestingly, holoprosencephaly is also a 
consequence of human heterozygous loss of function SHH mutations [322-324]. Lastly, 
Gli1/Gli2 double mutants, but not Gli1/Gli3 double mutants, exhibit fatal defects, including 
an impaired development of spinal cord cell types and smaller lung sizes, leading to death 
soon after birth; and still, these defects appear less severe than the lone Gli2 mutant 
[316]. This research suggests that Gli2 function may be much more elaborate than we 
currently understand, and certainly, the SHH pathway mechanisms mediating increased 
Gli2 activity, whether as an activator or repressor, are still unclear. Gli2 repressor activity 
has predominantly been explored in zebrafish, where Gli2 repressor activity has been 
shown to interfere with hedgehog signaling via Gli1 blockade [325], and disrupt 
differentiation and axon guidance in the ventral forebrain [326]. While the literature 
denotes Gli2 to function mainly as an activator in other animal models, its repressor 
behavior requires further investigation to elucidate the full extent of its role in neural tube 
development and telencephalic patterning, and especially its potential role in 
neurodevelopmental disease. Indeed, in vitro systems, such as the aforementioned 





























Figure 4.2: Gli Protein Expression Within the Neural Tube. Dorsal-ventral axis depicted with 
gradient expression of the dorsal Gli2 and Gli3, and ventral Gli1. Also illustrated is the anterior 
neural tube and SHH-secreting notochord. Where SHH and Gli1 are active, ventral interneurons 








Tourette Syndrome participants in this study were recruited at the Tic and Obsessive-
Compulsive Disorder Program at Yale Child Study Center by the teams of Dr. James 
Leckman, Dr. Robert King, and Dr. Michael Bloch. All Tourette Syndrome participants 
were evaluated in person or videoconference by Dr. Angeli Landeros-Weisenberger, a 
trained clinical researcher. Severity of symptoms was assessed using the ADSRS 
(Adult ADHD self Report Scale), the YGTSS (Yale Global Tic Severity Scale), the SCID 
(Structured Clinical Interview), the PUTS (Premonitory Urge for Tic Scale), the Y-BOCS 
(Yale-Brown Obsessive Compulsive Scale), the Hamilton Anxiety Rating Scale, and the 
LIFE-RIFT (Longitudinal Interval Follow-up Evaluation-Range of Impaired Functioning 
Tool). The criteria for inclusion are confirmed diagnosis of TS based on clinical 
evaluation and results of the diagnostic assessment. Participants were excluded if they 
have other psychiatric diagnoses, with the exception of OCD (Obsessive-Compulsive 
Disorder) and ADHD (Attention Deficit Hyperactivity Disorder), which do not represent 
exclusionary criteria because of frequent co-morbidity with TS.  
 
The healthy unaffected control participants in this study were recruited from a larger 
pool of participants evaluated through several research projects at the Yale Child Study 
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Center Autism Program by the teams of Drs. Katarzyna Chawarska, Pamela Ventola, 
and Kevin Pelphrey. 
 
All participants were asked to donate a small punch skin biopsy (about 3 mm) of the 
inner surface of the arm after topical anesthesia with lidocaine. Informed consent was 
obtained from each subject according to the regulations of the Institutional Review 













Primary cultures of fibroblasts were derived using standard explant procedures [327]. 
hiPSCs were generated using the original retroviral approach [240] or by a viral-free 
episomal reprogramming method [328]. See Table 2 for details. All iPSC lines used in 
 
Table 1: Subject Participants and iPSC Acquisition. This table outlines 
the Subject ID for the TS and CT individuals used in this thesis, and subject 
background and biopsy details. Age at the time of biopsy is in denoted in 
months since birth. 
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this study were characterized using three sets of quality control criteria: (1) morphology; 
(2) immuno-cytochemical expression of pluripotent markers, and (3) semiquantitative 
RT-PCR of pluripotency marker genes and downregulation of exogenous 
reprogramming factors. Whole Genome Sequencing for a subset of the iPSC lines used 
in this project has been previously analyzed [18, 329, 330]. 
 
The recruitment and production of iPSC lines for control subjects were supported by the 
following grants: MH087879, MH089176, and MH109648 from the National Institutes of 
Health, and by the Simons Foundation. 
The recruitment and production of iPSC lines for TS subjects were supported by 
MH118453 from the National Institutes of Health, and by NARSAD- Brain and Behavior 











Table 2: Subject diagnoses and details of iPSC generation. This table identifies further descriptors of 
recruited subjects and derived biopsies. Subject diagnoses as well as reprogramming methods of 


















Induced Pluripotent Stem Cells (iPSC) 
Fibroblast skin biopsies were taken from each individual utilized for this study and 
successfully reprogrammed to iPSC lines, both as previously described [13] and by 
integration-free methods (See Table 2). A total of 25 iPSC lines were utilized and 
differentiated for the data described (Table 1). Each of the iPSC lines for both TS 
probands (n=5 biological replicates; at least 2 clones were used per line = 12 lines total) 


Figure 1: TS fibroblasts were successfully reprogrammed to iPSCs. 
RT-PCR classification of 3 iPSC lines derived from TS patients TS02-03, 
TS03-03 & TS08-03. H1 hESC =positive control. Fibroblasts (Fib) and PCR 
negative control (Neg) =negative controls. (A) Pluripotent markers; (B) 
Endogenous and exogenous reprogramming genes; (C) Absence of 
episomal vectors. Transfected Fibroblasts (Pos) =positive control. 
Transgenes OriP and EBNA-1 can detected in all five episomal plasmids. 
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and the healthy CT individuals (n=11 biological replicates; 13 lines total) were generated 
by using either the classical Yamanaka retroviral approach or by non-viral episomal 
methodology [328]. The following CT iPSC lines were previously described: PGP1 [13, 
331]; 07-01 [18]; and 1123-01 [329]. The TS individuals’ iPSC lines are unpublished. 
The iPSC characterization and quality control  for TS individuals TS02-03, TS03-03 and 
TS08-03 are shown in Figure 1. 
 
Neuronal Differentiation 
For the investigations conducted in this thesis, I achieved telencephalic neural 
organoids favoring ventral forebrain development by differentiating the iPSC lines using 
a modified methodology for 3D organoids in suspension [13, 18]. Briefly, iPSCs are 
cultured to create 3D cellular aggregates called embryoid bodies. The floating embryoid 
bodies are maintained in suspension and stationary for one week under neuralizing and 
proliferative conditions. The neural aggregates form lumen-filled rosettes, which are 
manually harvested and cultured under potent ventralizing and growth-promoting 
conditions to generate basal ganglia organoids. Specifically, ventral morphogens – the 
SHH agonist purmorphamine (PUR, 2) and fibroblast growth factor 8 (FGF8, 
200ng/ml) – were added on Day 8 for 4 days (see Figure 1A for an outline). Terminal 
differentiation (TD) is deemed the day in which growth media are withdrawn and 
changed into differentiation-promoting media, which is day 12 from the beginning of 
culture. Upon entry into terminal differentiation, the then termed organoids are cultured 
for one week under ventralizing and maturation-promoting conditions. Specifically, PUR 
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Terminal differentiation and maturation-promoting conditions are continued up to one 
year. Differentiations for both TS probands and healthy CT individuals were conducted 
in parallel for each preparation. Please see the full basal ganglia organoid protocol in 
the appendix of this thesis, and the schematic illustrated in Chapter Four, Figure 1 of 
this thesis. 
 
RNA Isolation, qPCR and RNA Sequencing Experiments 
RNA was extracted from basal ganglia organoids on day 12 (TD0), 26 (TD14) or 38 
(TD30) in vitro, as previously described [13]. For each time point, 16-20 organoids were 
harvested and pooled for material. Briefly, the PicoPure RNA isolation kit (Applied 
Bioscience) was utilized, according to the manufacturer’s instructions, to isolate total 
RNA from harvested organoids. The RNA from these extractions were used for both 
qPCR and RNA sequencing. To perform qPCR for both culture characterization and 
RNA sequencing validation, cDNA was first synthesized utilizing the SuperScript III 
First-Strand Synthesis Kit and random hexamers (Invitrogen) using 100 ng of total RNA 
as starting material. The StepOnePlus Real-Time PCR System (Applied Biosystems) 
was used to complete qPCR experiments, using Power SYBR Green PCR Master Mix 
(Applied Biosystems); the samples were normalized to GAPDH housekeeping gene 
expression. qPCR data were analyzed using a Two-Way ANOVA and post hoc test to 
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establish significance of gene expression. Please see Table 3 below for the primer 

















For RNA sequencing experiments, RNA was extracted for identical timepoints as with 
qPCR – day 12 (TD0), 26 (TD14) or 38 (TD30) in vitro. HiSeq paired-end, 100 bp RNA 
sequencing (with rRNA depletion) was conducted on a NovaSeq platform to a 

 
Table 3: List of primers used for qPCR analysis. Forward and Reverse primer sequences are 
noted, as well as the publication from which they were used. 
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sequencing depth of 40 million reads per sample. Two batches of samples were 


















Immunostaining and Stereology 
Basal ganglia organoids were harvested and visualized at day 26 (TD14) or 38 (TD30) 
in vitro. Samples were prepared as previously described [18]. For each time point, 5-10 
 

Figure 2: Principle Component Analysis (PCA) from RNA sequencing submissions shows no batch 
effect. Both submissions (submission 1: circle – RQ12875; submission 2: triangle – RQ13274) cluster 
similarly, with no obvious separation between samples attributed to separate submissions. PC1 (along X 
axis) shows that the strongest separation (33.49%) between samples is driven by time, as TD0 samples 
are sharply separated from TD14 and TD30 samples. PC2 (Y axis) shows that the next separation is 
attributed to individual background (TS vs CT); however, this separation is not as strong. These trends 
follow typical findings from patient and control PCA. 
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organoids were pooled per line and fixed in 4% PFA for 3 hours. The samples were 
subsequently incubated in 25% sucrose overnight. After removal from sucrose solution, 
each organoid was immediately embedded in OCT while at room temperature and 
stored at -80 degrees Celsius. For further empirical use, the embedded samples were 
crysectioned at 12 μm. For immunostaining, the cryosections were first incubated at 
room temperature for 1 hour in blocking solution (10% donkey serum/0.1% Triton X-100 
in PBS). Samples were treated with primary antibodies that were placed in diluted 
blocking buffer (5% donkey serum/0.05% Triton X-100 in PBS); sections were incubated 
overnight at 4 degrees Celsius. The sections were subsequently washed three times in 
5 minute periods in PBS/0.1% Triton X-100. Next, sections were treated for 1 hour at 
room temperature with secondary antibodies (1:500, Alexa or Jackson Laboratories) in 
diluted blocking buffer. Primary antibody dilutions are as follows: PAX6 (mouse, BD 
Bioscience, #561462, 1:200); N-cadherin (mouse, BD Bioscience, #610920, 1:500); 
TBR1 (rabbit, Abcam, #ab31940, 1:1000); SOX1 (goat, R&D System, #AF3369, 1:20); 
DLX-2 (rabbit, gift of Yuri Morozov, Yale University, New Haven, CT, 1:1000); NKX2.1 
(mouse, Thermo Scientific, #MA5-16406, 1:200); BRN2 (goat, Santa Cruz, #sc-6029, 
1:100); Ki67 (rabbit, Vector, #VP-RM04, 1:500); pH3 (rat, Sigma, H9908, 1:1000); 
CHAT (goat, Chemicon, #AB144P, 1:1000). 
 
For image acquisition, an ApoTome-equipped Axiovert 200M with Axiovision 4.5 
software was used. Stereological analysis was performed to quantify immunostained 
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cells utilizing a Carl Zeiss Axioskop 2 Mot Plus, which was connected to a computer 
running Stereoinvestigator software (MicroBright-Field). 
For quantification, two organoids and four sections per organoid (per individual) were 
used. The optical fractionator probe (100x oil-immersion objective) was utilized to count 
the nuclear profiles of stained cells. The percentage of positive cells were calculated 
relative to total DAPI+ cells. 
 
Western Blotting 
Western blot experiments were conducted on basal ganglia organoids day 12 (TD0) in 
vitro, as previously described [18]. For protein extraction, basal ganglia organoids were 
first washed with cold PBS before treated with complete Lysis-M, EDTA-free buffer 
(Roche, 04 791 964 001), which was additionally supplemented with protease (Roche, 
11 836 170 001) and phosphatase inhibitor cocktail tablets (Roche, 04 906 837 001). 
Samples were then centrifuged for 15 minutes at 14000 rpm at 4 degrees Celsius. Next, 
the supernatant fraction was obtained and the total protein per sample was quantified 
using the QubitTM Protein Assay Kit (Invitrogen, #Q33211). For each protein gel, 40 μg 
total protein per sample was loaded into TGX stain-free 4-15% precast gels (BioRad, 
#P4568084) and SDS gel electrophoresis was performed. The gels were subsequently 
transferred to nitrocellulose membranes (BioRad, #1704158). For this thesis, all 
membranes were visualized using SuperSignal West Pico Chemioluminescent 
Substrate (Thermo Scientific, 34080) and quantified using ImageJ software. Primary 
antibodies were diluted as follows: GLI1 (rabbit, Abcam, #ab134906, 1:500 ); GLI2 
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(rabbit, Millipore, #ABN2241, 1:500 ); GLI3 (rabbit, Abcam, #ab6050, 1:500 ); GAPDH 
(mouse, Millipore, MAB374, 1:1000). 
 
Transcriptome Analysis by RNA sequencing  
RNA-seq data analysis.  
We used STAR [334] to map the reads to the human genome (hg38) and the 
GencodeV34 for transcriptome annotation. The mapped reads were sorted by 
coordinates in BAM file format using SAMtools [335]. Gene expression in counts was 
estimated using the RSubread function featureCounts [336]. Gene expression in RPKM 
was estimated using the edgeR function rpkm [337]. All the heatmaps were plotted 
using log2(1+rpkm) values scaled at row level. Differential expression analysis has been 
performed between controls and probands at TD0, TD14 and TD30 by using edgeR 
[337] functions glmFit and glmLRT and using trended dispersions as dispersion input. 
Lowly expressed genes have been filtered before analysis by using edgeR function 
filterByExpr. An FDR cut-off of 0.05 was used for all the tests. For GO term and 
canonical pathway enrichment analysis, we used ConsensusPATH tool [338]. 
Differentially expressed genes were identified using a base limit corrected P value 
(FDR) of <0.05 and a fold change of +/-2. Heatmaps were generated using RPKM 






Results: Ventralizing the organoid system – the basal ganglia protocol 
 
We previously developed a cortical organoid model to examine pathogenesis of ASD 
[13, 18], and I since have employed modifications to enrich for a basal ganglia-like 
cellular commitment within the organoids. Selecting for a ventral specification fosters 
basal ganglia-like neural organoid development and enables the study of cellular and 
molecular characteristics of neuronal precursors in TS. Our findings show that 
optimizing timing and concentration of a cocktail of ventral morphogens induce ventral 
telencephalic organoid development (Figure 1), triggering necessary transcriptional 
programming to generate BG-like organoids. 
 
The Protocol for Differentiating Basal Ganglia-like Organoids 
To obtain neural organoids enriched with ventral telencephalic precursors, manually 
selected free-floating neural rosettes are cultured in serum-free medium supplemented 
with fibroblast growth factor 2 (FGF2) and epidermal growth factor (EGF) (10ng/ml 
each) plus the sonic hedgehog (SHH) agonist purmorphamine (PUR, 2) and 
fibroblast growth factor 8 (FGF8, 200ng/ml) for 4 days (Figure 1A). Adding these two 
essential ventral morphogens during the proliferative phase of organoid development is 
the initial trigger to shift cellular commitment away from the default dorsal telencephalic 
fate [11-14] and towards a ventral one. Further, this addition activates the crucial early 
ventral forebrain determinant, NKX2.1, the transcription factor that pioneers ventral 
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telencephalic development [339] and is absent in cortical cultures (Figure 1B). After 
these 4 proliferative days, organoid cultures are differentiated in neurobasal media 
supplemented with brain-derived neurotropic factor (BDNF), glial cell line-derived 
neurotropic factor (GDNF), Ascorbic Acid and dibutyryl-cAMP. Upon entry into the 
terminal differentiation phase of organoid development, PUR and FGF8 are added at a 
reduced concentration (PUR, 1'()(&$**+ ,	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Figure 1: Organoids from iPSCs are enriched for ventral telencephalic development. (A) 
Schematic of the ventralized basal ganglia organoid protocol. (B) Immunostaining at terminal 
differentiation time points early TD14 and late TD30, showing increased expression exclusive to the 
ventral telencephalon. In contrast to the cortical organoids (Mariani, 2012), ventralized organoids have 
larger numbers of NKX2.1+/CHAT+ cells (putative MGE-type interneurons) and smaller numbers of 
PAX6+ cells (dorsal cortical progenitors and neurons). ( C) Heatmaps of a set of DGEs from bulk RNA-
sequencing analyses (P < 0.05) show the differential pattern of topographical (Dorsal, LGE, MGE, 
POA) gene expression in basal ganglia versus cortical organoids N=6 CTX; N=6 BG. Log2(1+rpkm) 
values were scaled in each row and heatmapped. (D) RNA sequencing findings are validated by 
qPCR. CTX samples are annotated in black; BG samples are annotated in blue. Statistics are done by 
Two-Way Anova analysis: Dorsal (P < 0.0001); LGE (P=0.0063); MGE (P=0.0329); POA (P=0.008). 
CTX is used as a reference (measuring as 1 in the graph); all quantifications were normalized to the 
housekeeping gene GAPDH. N=7 CTX; N=7 BG (E) Organoids were transduced at 6 months of age 
with SYN-GFP and visualized by two-photon microscopy to visualize overall health and spine 
development. (N=2)
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Bulk RNA Sequencing Show Ventral Shifts in Gene Expression 
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Real Time qPCR Validate Ventral Shifts in Gene Expression 































Supplemental Figure S1: Additional immunostaining comparing cortical and basal ganglia 
organoids and stereological counts. (A) Staining of ventral progenitor DLX and cortical TBR1 in 
cortical and basal ganglia organoids. (B) Stereological counts quantifying immunostaining in A. ( C) 
Stereological counts of immunostaining for CHAT, NKX2.1 and their co-localization at TD11 
between cortical and basal ganglia preparations. (D) C repeated at TD33. (E) Stereological counts 
quantifying immunostaining of cortical preparations comparing TD11 and TD33 for CHAT, NKX2.1 
and their co-localization. (F) Stereological counts quantifying immunostaining of basal ganglia 
preparations comparing TD11 and TD33 for CHAT, NKX2.1 and their co-localization. Classical 
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Collectively, gene and protein expression in ventralized organoids are consistent with 
differentiation into ventral progenitors, indicative of MGE, LGE and POA development, 
as well as striatal post-mitotic neuronal development. Additionally, and importantly, 
dorsal gene expression is downregulated in the basal ganglia organoids, which is 
consistent with correct patterning and mimic mammalian (including human) 
neurodevelopment. Next, I applied this basal ganglia protocol to examine the early 





















While roughly 75% of TS patients’ tic symptoms fade as they enter adulthood (remitted 
TS), 1/4 of TS patients experience persistent mild or severe symptoms of TS throughout 
the entirety of their lives (unremitted TS) [6, 71]. Pathogenesis of either patient category 
is largely unknown. Smaller caudate volumes in children with TS have served as a 
predictor of unremitting TS [7], and support the hypothesis that TS biologically manifests 
during early development. In this chapter, we utilized the BG organoid protocol 
described in Chapter 4 of this thesis (Chapter 4, Figure 1A) to compare the 
neurodevelopment of the ventral telencephalon between severe unremitting TS adult 
individuals (n=5) and healthy controls (CT, n=10) (Chapter 3, Table 1). To accomplish 
this, we recruited TS individuals from our Tourette/OCD clinic at the Child Study Center 
and generated iPSC lines using both integrating-non-integrating methods (See Chapter 
3, Tables 1 & 2). This facilitated my subsequent experiments where these iPSC lines 
were differentiated into ventral telencephalic progenitors and compared to CT lines 
obtained from the Vaccarino lab iPSC biobank (see Table 1) using the BG organoid 
model (Chapter 4, Figure 1A). 
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Patient iPSC-Derived Basal Ganglia Organoids Show Disrupted 
Organization and Ventral Expression  
 
In the following studies we used 5 biologically distinct iPSC lines for TS probands, with 
2 distinct iPSC clones per individual, and 10 biologically distinct iPSC lines for CT. All 
lines were utilized for neuronal differentiation studies and analyzed at three time points: 
TD0, TD11 and TD30. All lines were used for RNA-seq studies, except that 4 
biologically distinct TS iPSC lines (rather than 5) were used at TD0.  For a general over-
view of TS vs CT organoid transcriptome profiles, samples were submitted for bulk RNA 
sequencing for transcriptome profiling across time for TD0, TD14 and TD30; a total of 2 
submissions were made, but no batch effect was observed (See Chapter 3, Figure 2). 
 
Overall DGE  
When assessing the overall DGE profiles across patient and CT individuals there are 
general conclusions that can be made. The majority of differentially expressed genes 
that are upregulated are seen early on, at TD0 (309) (Figure 2A), while the majority of 
differentially expressed genes that are downregulated are seen at the latest stage, at 
TD30 (581) (Figure 2B). Additionally, there is little overlap between the differentially 
expressed genes (DEGs) identified at different developmental time points, suggesting 
that the changes in gene expression are generally time-specific. The data reveal that, 
when combining the three time points  and direction of differential gene expression (up 
and downregulation), there are 1512 DEGs in total (Figure 2C). When disregarding time 
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and performing a combined DGE analysis across all data, there are only 881 DEGs, of 
which 705 overlap with the union of the time-specific DEGs (Figure 2C). Therefore, 
there are only 176 novel DGE additionally obtained from the combined analysis despite 





















Figure 2: Bulk RNA-Sequencing analysis showing overall DGE when comparing TS vs CT across 
time. (A) A Venn diagram showing number of upregulated genes across TD0, TD14 and TD30. (B) A 
Venn diagram showing number of downregulated genes across TD0, TD14 and TD30. ( C) A Venn 
diagram showing number of combined DGE from all 3 time points (red) vs DGE from a pooled analysis 
disregarding time (DGE_pooled). (D, E and F) DGEs plotted on volcano plots for TD0 (D), TD14 (D) and 
TD30 (F), using significance by corrected p value (Y axis, FDR) and fold change (X axis, logFC). Top 
most significant up and downregulated genes were labeled. For TD0, N=4 CT; N=5 TS. For TD14, N=5 




The DEGs were then ranked by significance (y axis, -logFDR) and fold change value (x 
axis, logFC) and displayed in volcano plots across time, for TD0, TD14 and TD30. 
General conclusions can also be determined from these graphs. The trends observed 
from the Venn diagrams in panels A-C (Figure 2) are reiterated in the volcano plots, 
where the most upregulated genes in TS individuals are seen at TD0, while more 
downregulated genes in TS individuals are seen at TD30. Interestingly, at TD0, many of 
the most significantly upregulated genes by both FDR and fold change are HOX genes. 
These genes are mostly expressed in the brainstem and are therefore indicative of a 
posterior fate. At TD14, CNTN4 is among the top most significant downregulated genes 
in TS, a gene that has previously been linked with the disorder [23, 351]. With this 
foundational overview of developmental changes across TS and CT individual-derived 
basal ganglia organoids, the three time points are further explored in the following 
sections. 
 
Functional Annotations of DGE Analyses 
With general DGE lists generated across time as shown in Figure 2, we ran functional 
annotation analyses to bring greater understanding and context to their expression 
changes. Enrichment analyses among downregulated and upregulated genes were 
performed using the ConsensusPathDB platform from Max Planck Institute 
(http://cpdb.molgen.mpg.de/) for GO (Gene Ontology) terms at all three timepoints – 
TD0, TD14 and TD30. Focusing closely on the top 10 most significant (P value < 0.05) 
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GO terms offered an unbiased approach to the understanding of developmental shifts 
identified in the TS-derived organoids.  
 
TD0 
Among the top 10 most significant downregulated GO terms for DGE at TD0 (Figure 
3A), categories surrounding nervous system development and neurogenesis are 
generally evident. As current postulates in the TS field revolve around basal ganglia 
circuitry dysfunction, I took great interest in GO term #7, Regulation of Trans-Synaptic 
Signaling encompassing several DEGs related to synaptic function (Figure 3B), which 
will later be revealed as a consistent downregulated category across time. When 
looking at the top 10 most significant upregulated GO terms for TD0 (Figure 3C), 
additional neurodevelopmental categories are noted. In line with the observations seen 
in the volcano plot at TD0 (Figure 2D), GO term #9 identifies Anterior/Posterior Pattern 
Specification; when compiling the list of DEGs for this category, the lists reveal many 
HOX and WNT genes more highly expressed in TS-derived basal ganglia organoids 
than in CT (Figure 3D). This suggests an early preference for a posterior fate in the TS-
derived organoids. Further categories include the manually curated SHH signaling for 
downregulated genes, and the additional GO term category of interest, while not among 
the top 10 most significant, Midbrain patterning (P Value = 3.23E-07) for upregulated 
genes (Figure 3E). Enrichment in these categories and expression trends of the related 
DEGs reiterate the potential decreased ventral commitment in the TS-derived basal 























For TD14, experimental analysis was expanded to include three separate assays – 
immunocytochemistry, qPCR and RNA sequencing analyses. In line with a potentially 
compromised ventral telencephalic commitment seen at TD0 (Figure 3), my data reveal 
a strong cellular phenotype, with decreased NKX2.1 gene expression in TS basal 
ganglia organoids via real-time qPCR, confirmed by representative images of 
immunostaining (Figure 4A,B). To determine a potential consequence of this loss and 
identify disruptions in post-mitotic gene expression, we investigated the specific 


Figure 3: GO term analysis at TD0. (A) Top 10 most significantly downregulated GO terms that meet 
significance (P < 0.05). (B) Heatmap of the DGEs associated with the GO term #7 from top 10 from 
panel A. ( C) Top 10 most significantly upregulated GO terms that meet significance (P < 0.05). (D) 
Heatmap of DGEs associated with the GO term #9 from top 10 from panel C. (E) Additional heatmaps 
of DGEs associated with relevant patterning categories from GO term analysis, SHH and Midbrain. For 
all TD0 RNA sequencing, N=5 TS; N=4 CT were submitted for analysis. All heatmaps show 
log2(1+rpkm) values were scaled in each row. 

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cholinergic interneuron population via immunostaining to reveal an absence of CHAT 
expression in TS organoids (Figure 4A). I expanded our analyses to target the same 
topographical areas that I focused on during protocol optimization (Chapter 4, Figure 1C 
&1D) to reveal that significant patterning abnormalities are apparent at TD14 (Figure 4B 






















Figure 4: TD14 TS Basal Ganglia organoids show a decreased ventral patterning and increased 
dorsolateral commitment. (A) Representative immunostaining shows reduced NKX2.1 and CHAT 
expression in TS-derived basal ganglia organoids. Experiments were repeated with similar results (N=3 
TS; N=3 CT). (B) Validation via qPCR analysis show TS organoids (red triangle) exhibit loss of 
NKX2.1+ expression, GABA and cholinergic interneurons, and increased expression of LGE and dorsal 
cortex markers as compared to CT (black circle). Statistics are done by Two-Way Anova analysis: 
Dorsal (P < 0.0001); LGE (P=0.0108); MGE (P=0.0171); POA (P=0.0003). N=5 TS (2 clones each = 10 
lines); N=10 CT. ( C) Heatmaps of a set of DGEs from bulk RNA-Sequencing analysis (P < 0.05) show 
topographical (Dorsal, LGE, MGE, POA) gene expression of basal ganglia organoids in comparison to 
cortical organoids. N=5 TS; N=5 CT. Log2(1+rpkm) values were scaled in each row and heatmapped. 
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Analyses of RNA via real-time qPCR show overall reduction in medioventral gene 
expression, disrupting both MGE and POA identities. Essential genes expressed in 
progenitors of these regions, including NKX2.1, DLX, LHX8 and ISL1, show reductions 
consistent across all 5 TS individuals (Figure 4B), along with post-mitotic neuronal 
machinery of both GABAergic and cholinergic interneurons which are derivatives of the 
MGE and POA and observed via both qPCR (Figure 4B) and RNA sequencing (Figure 
4C). Remarkably, the medioventral loss is accompanied by an upregulation of 
dorsolateral gene expression, enhancing dorsal and LGE identities within the TS basal 
ganglia organoids, and observed via both qPCR (Figure 4B) and RNA sequencing 
(Figure 4C).  
 
With the developmental deficits apparent so strongly at TD14, suggesting mispatterning 
and topographical shifts in telencephalic growth, I wanted to investigate further at the 
RNA sequencing scale. Functional annotation analyses were completed for TD14 
(Figure 5) to explore the biological significance of the transcriptional alterations in the 
TS individuals. The top 10 most significant downregulated GO terms (Figure 5A) revolve 
heavily around cellular development and signaling components, such as cilia. I first 
focused on GO term #7, which is Extracellular Matrix Organization (Figure 5B). Many of 
these DEGs are collagen and laminin-related, all of which are significantly reduced in 
expression in TS-derived basal ganglia organoids. Although the significance of this 
finding is not yet fully clear, these downregulated genes could suggest a potential 
reduction in cellular stability and support, an altered cell polarity (which has been 
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postulated in TS [82] as well as a hindrance of complex cellular signaling [264, 352, 
353]. A deeper look into the GO terms reveal additional signaling categories, including 
Trans-Synaptic Signaling (P Value = 0.00833) (Figure 5C) and Serotonergic Signaling 
(P Value = 0.00668) (Figure 5D), both of which show significant enrichment among 
downregulated genes. The Trans-Synaptic Signaling gene list is more elaborate now at 
TD14 than what was seen at TD0, and the consistency in this category across time is 
important to note. Additionally, serotonergic neurons traverse the human brain, 
extending from the hindbrain and innervating various regions of the cerebrum, including 
the basal ganglia. Deficits in serotonergic expression have previously been described in 
TS transcriptome [10] and serotonergic signaling has been previously implicated in TS 
[354-357], making this category of particularly high interest. When examining the top 10 
significantly upregulated GO terms (Figure 5E), additional neurodevelopmentally-related 
categories appear. Focusing on both Embryonic Axis Specification (GO term #3) (Figure 
5F) and Nervous System Development (GO term #7) (Figure 5G), posterior WNT and 
PAX3 genes are upregulated in TS, as well as the LGE-specific GSX2 gene. These 
enrichments further signify a mispatterning away from the typical anterior-ventral 
telencephalic fate in the TS-derived basal ganglia organoids. Further, another 
upregulated GO term interesting to note is the Glycosphingolipid Synthesis gene 
category (Supplementary Figure S2). While there are only two genes identified for this 
category, the expression trend is strong and consistent across all 5 TS-derived basal 
ganglia organoids, with very little variability. This category is interesting due to its past 
linkage to Parkinson’s Disease, both a movement disorder and one whose etiology is 
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rooted in the basal ganglia [358]. These parallel with TS emphasizes Glycosphingolipid 

















For TD30, for emphasis on consistent expression trends and categories, I will begin with 
the description of the top 10 most significant upregulated GO terms (Figure 6A). 
Immediately apparent, categories signifying caudal expression in the TS-derived basal 
ganglia organoids are plentiful even among only the top 10. There are two different 
spinal cord-related categories, and the #1 most significant GO term is Spinal Cord 

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Figure 5: GO term analysis at TD14. (A) Top 10 most significantly downregulated GO terms that meet 
significance (P < 0.05). (B) Heatmap of the DGEs associated with the GO term #7 from top 10 from 
panel A. ( C) Heatmap of the DGEs associated with the additional GO terms for relevant signaling 
disruptions, Trans-Synaptic and Serotonergic Signaling (D) Top 10 most significantly upregulated GO 
terms that meet significance (P < 0.05). (E and F) Heatmap of the DGEs associated with the GO term 
#3 (E) and GO term #7 (F) from top 10 from panel C. (G) Heatmap of the DGEs associated with the 
additional GO term for gene category previously linked with movement disorders, Glycosphingolipid 
Synthesis. For all TD14 RNA sequencing, N=5 TS; N=5 CT were submitted for analysis. All heatmaps 
show log2(1+rpkm) values were scaled in each row. 

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Development (Figure 6B), where the list of DEGs in intersection further indicates a 
posterior preference. The #2 GO term is Dorsal/Ventral Pattern Formation (Figure 6C), 
where the listed upregulated DEGs in TS favor a dorsal fate. These two gene sets 
reiterate the previously suggested fate shifts within the TS-derived basal ganglia 
organoids whereby the cells show a preference for a dorsal and posterior fate, instead 
of a ventral-anterior one.  
Additional support for this comes from the Anterior/Posterior Pattern Specification GO 
term (P Value = 4.43E-05) (Figure 6D), which is not in the top 10 Go terms, but where 
the genes favor a posterior fate with consistent upregulations in HOX genes. A curated 
gene list for LGE/CGE development (Figure 6E) further confirms an apparent fate shift 

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Figure 6: Top Upregulated GO term analysis at TD30. (A) Top 10 most significantly up-regulated 
GO terms that meet significance (P < 0.05). (B) Heatmaps of the DGEs associated with the GO 
terms #1 and ( C) #2 from top 10 from panel A. ( D) Heatmaps of the DGEs associated with the 
additional GO term for relevant patterning disruptions, Anterior/Posterior Pattern Specification. (E) 
Heatmap of the manually curated DGEs associated with the LGE emphasizing addition patterning 
shift. For all TD30 RNA sequencing, N=5 TS; N=5 CT were submitted for analysis. All heatmaps 
show log2(1+rpkm) values were scaled in each row. 

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away from a ventral-anterior fate with upregulations in the lateral GSX2, and the caudal 
GBX2, PAX3 and TBX10 among the list. Additionally, Glycosphingolipid Synthesis 
appears as another GO term not in the top 10 (Supplementary Figure S2), with the 
same two genes expressed with similar strikingly evident trends of upregulation in the 
TS-derived basal ganglia organoids. The consistency across these categories, spanning 
from early organoid formation to later more mature time points, brings greater emphasis 
to the altered transcriptional programming and mispatterning evident in TS-derived 
basal ganglia organoids.  
 
To begin the examination of downregulated genes at TD30, I am highlighting among the 
top significant GO terms (Figure 7A) GO term #1, Extracellular Matrix Organization, 
which is an extension of what was defined at TD14 (Figure 7B) and GO term #6,  
Regulation of Cell Motility (Figure 7C). These two categories are related in their roles of 
cellular development, stability and signaling, and also in their expression trends, where 

 
Supplemental Figure S2: Glycosphingolipid Synthesis. Enrichment for the GO terms Glycosphingolipid 
Synthesis across TD14 and TD30 show consistent upregulation across all 5 TS samples. For all TD14 and 
TD30 RNA sequencing, N=5 TS; N=5 CT were submitted for analysis. All heatmaps show log2(1+rpkm) 
values were scaled in each row. 

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the downregulation observed in TS samples is driven largely by two control samples 
with strong expression of the listed genes. However, for the consistency in the 
conceptual relationship to this thesis, I felt these unbiased gene lists were important to 
describe. 
When looking deeper at more clinically relevant downregulated GO term categories, 
several are integral to TS etiology, even though they are not among the top 10 
categories. Beginning with Tran-Synaptic Signaling (P Value = 3.91E-08), what can be 
appreciated from this list (Figure 8A) is its abundance in comparison to that at TD14 or 
TD0. The consistency not only across time but also in this category’s potential role in 
the TS-derived basal ganglia organoids’ development is remarkable. Building off of the 

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Figure 7: Top downregulated GO term analysis at TD30. (A) Top 10 most significantly 
downregulated GO terms that meet significance (P < 0.05). (B) Heatmaps of the DGEs associated 
with the GO terms #1 and #6 from top 10 from panel A. For all TD30 RNA sequencing, N=5 TS; N=5 
CT were submitted for analysis. All heatmaps show log2(1+rpkm) values were scaled in each row. 

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conceptual significance noted at TD0, deficiencies in synapse development and hence 
trans-synaptic signaling potentially have a profound role in TS.  
 
With basal ganglia developmental dysregulation at the forefront of the field’s general 
understanding of disorder causality, synaptic signaling becomes an important piece of 
the TS story when determining the ability of multiple brain regions within the cortico-
striatal-thalamic circuit to cross-talk effectively, especially in view of the hypothesized 

















Figure 8: Additional downregulated GO term analyses at TD30. (A) Heatmap of the DGEs 
associated with the Trans-Synaptic Signaling (B) Heatmap of the DGEs associated with the 
Serotonergic Synapse ( C) Heatmap of the DGEs associated with the GABAergic Synapse and 
Signaling (D) Heatmap of the DGEs associated with the Nitric Oxide-mediated Signaling. (E) 
Heatmap of the DGEs associated with the Post Synaptic Regulators (F) Heatmap of the manually 
curated DGEs associated with POA. For all TD30 RNA sequencing, N=5 TS; N=5 CT were submitted 
for analysis. All heatmaps show log2(1+rpkm) values were scaled in each row. 

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Further support of these points are that multiple types of synapses are downregulated in 
the TS-derived basal ganglia organoids. For instance, the Serotonergic Synapse term 
(P Value = 0.00313) (Figure 8B) is another large gene list, much expanded from TD14. 
Additionally, GABAergic Synapse and Signaling (P Value = 2.30E-05) (Figure 8C) are 
both perturbed in TS-derived basal ganglia organoids. Nitric Oxide-mediated Signaling 
(P Value = 0.00134) (Figure 8D) is also downregulated across TS individuals, which 
agrees with deficiencies in number of NOS-containing interneurons found in adult basal 
ganglia of TS individuals (Lennington et al; Chapter 1B, Fig. 11.2). Post-Synaptic 
Regulators (P Value = 1.78E-05) is another GO term aligning with these classifications 
(Figure 8E). Finally, genes specific for POA development continue to be significantly 
downregulated as represented in a curated list and corresponding heatmap (Figure 8F). 
In conclusions, the data support that signaling of serotonergic, GABAergic and specific 
interneurons such as the cholinergic and NOS types is perturbed in TS-derived basal 
ganglia organoids. These developmental disruptions affect both what is produced 
inherently by the basal ganglia (GABAergic; nitric oxide; cholinergic), and what is 
received by it (serotonergic). Finally, revisiting the overall DGE analyses from Figure 2, 
it is relevant to reiterate that the overlap of DGE across time is minimal. Therefore, while 
several of the gene categories are consistent over the three time points – TD0, TD14 
and TD30 – the gene lists vary substantially and further underscore their functional 
convergence even if there is minimal intersection across time. 
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Expression Trends Align with Adult Human TS Post-Mortem 
Data 
Previously published transcriptome data of adult human TS post-mortem brain tissue 
[10] has served as a foundation and motivation for this study, the experimental 
trajectory and the data described in this thesis. I referenced the previously published 
DEGs from post mortem TS tissue [10] with those obtained from the TS-derived basal 













From a total of 1131 DEGs obtained from post mortem TS tissue, 20 were manually 
curated and highlighted as particularly interesting in our previous publication (see Table 
1 in Lennington et al [10]); of these 20 manually curated DEGs, 6 were found to overlap 


Table 1: Expression trends overlap with adult human TS post mortem Data. A manually curated 
gene list from TS post mortem brain tissue was compared with DEG from TS basal ganglia organoids 
to find overlap in gene categories. Strategies listed for comparison include postmortem tissue analysis 
and two organoid time points – early TD14 and late TD30. FC, fold change; FDR corrected p value, 
false discovery rate. 
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in the same direction with DEGs obtained from the TS organoids (Table 1). The gene 
categories also follow both the post mortem classifications as well as the 
aforementioned sequencing GO term analyses. These include cholinergic, GABAergic 
and serotonergic genes. This table offers further support for the findings and 




These data suggest a potential shift away from an anterior-medial-ventral fate in TS 
patient-derived organoids. Concordant with the hypothesis of an MGE deficit in TS 
organoids, these data reveal an increase in some cortical and LGE genes, while also 
revealing a preference for a posterior fate within the TS BG organoids as compared to  
healthy CT-derived basal ganglia organoids, differences that are consistent across all 
three time points. Multiple assays at both RNA and protein levels further confirm this 
cellular signature. The gene categories affected a range of different cell types both 
present within the basal ganglia and those that, in the human brain, send projects to this 
subpallial region. The gene trends also follow previously published trends seen in adult 
human TS post mortem brain tissue. Together, these data show that deficits observed 
at the adult level are also seen at the embryonic/fetal level, and possibly arise from 






Mechanism of mispatterning in Tourette Syndrome 
 
 
Altered SHH Pathway and Primary Cilium Development in 
Basal Ganglia Organoids from TS Patients 
 
Given the significant deficit in ventral telencephalic development observed within the 
TS-derived BG organoids, I next wanted to investigate possible contributors to the 
detected developmental deficit. I focused on the SHH pathway because of its central 
involvement in basal ganglia development and its alterations evident in organoid 
transcriptomes. SHH signaling transduction takes place within microtubular organelles 
called primary cilia [260, 359, 360]. During embryogenesis, primary cilia protrude from 
nearly every vertebrate cell, conducting signal transduction. Because of their connection 
with SHH signaling, primary cilia are critical for facilitating dorsoventral patterning within 
the telencephalon [361]. The SHH pathway exists in two states with opposing functions 
(Figure 9A). In the dorsal telencephalon, the SHH pathway is in its inactive state. The 
SHH ligand is minimally expressed dorsally [362]; in its absence, the 12-transmembrane 
SHH receptor, Patched 1 (PTCH1), inhibits the 7-transmembrane G-protein coupled 
receptor Smoothened (SMO), thwarting its accumulation at the cilium surface [362, 
363]. With SMO repressed, two intracellular GLI transcription factors, GLI2 and GLI3, 
are phosphorylated and then proteolytically lysed to generate truncated repressor forms 
of both proteins, GLI2R and GLI3R [362]. Subsequently, these repressor proteins 
translocate to the nucleus of the cells where they inhibit transcription of downstream 
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SHH target genes (Figure 9A). The inhibition of the SHH signaling pathway in the dorsal 
telencephalon allows cortical gene expression to thrive by default, resulting in dorsal 
specification of this domain. Instead, within the ventral telencephalon, SHH ligand is 
potently expressed. In the presence of the SHH ligand, the PTCH1 receptor relieves its 
inhibition of SMO [5]. With SMO now active, GLI1 is the dominant intracellular 
transcription factor, which ultimately translocates in its full-length form into the nucleus, 
where it activates transcription of downstream SHH genes (Figure 9A). The activation of 
the SHH signaling pathway in the ventral telencephalon activates the NKX2.1 gene 
within ventral progenitors that give rise to the post-mitotic neurons that are exclusive to 
the basal ganglia [5]. 
 
I focused on these important proteins to determine if potentially disrupted SHH signaling 
in the TS patient-derived BG organoids could explain the patient organoid mispatterning 
phenotype observed. To move forward with these analyses, I concentrated on the early 
culture time point, TD0. To briefly review, in the development of the organoids, TD0 
marks the 4th day post-exposure to SHH and FGF8 (Figure 1A), an incubation period 
responsible for triggering a ventral telencephalic cellular commitment and regional 
identity. It is only after prolonged exposure to high concentrations of these morphogens 
that downstream SHH targets begin to be transcribed [4]. With this reasoning, TD0 was 
the logical time point to investigate potential differences in the proteins that orchestrate 
downstream SHH signaling, which could potentially underlie the phenotype observed at 

















By real-time qPCR, while expression level of the surface SHH receptors were not 
significantly altered, I found altered GLI protein expression. Across all 5 TS patients, 
their BG organoids showed significantly increased expression of the GLI2 and GLI3 
genes (Figure 9B), both of which can act as repressors of the SHH pathway (Figure 
9A). However, RNA expression cannot determine whether or not the truncated 
repressor form of the protein is expressed. Therefore, to examine levels of the potential 
repressor forms of the GLI2 and GLI3 proteins, I performed western blots on organoids 


Figure 9: Upregulation of GLI genes and disruption of cilia in TS-derived basal ganglia 
organoids. (A) Schematic of SHH signaling in dorsal and ventral contexts. (B) qPCR from TD0 
examining expression levels of key SHH signaling players. ( C) Western blots to determine expression 
of GLI Repressor proteins in TS-derived basal ganglia organoids. (Please see Supplemental Figure 3 
for additional western blots with Full Length (FL) expression) (E) Protein bands quantified by ImageJ 
software (N=4 CT; N=5 TS) (E) Revising top 10 most significantly downregulated GO terms that meet 
significance (P < 0.05) at TD14 showing ciliary disruptions. For all TD14 RNA sequencing, N=5 TS; 
N=5 CT were submitted for analysis.  

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from the TS and NC  cohort (Figure 9C). Remarkably, prominent bands for the 
truncated repressor forms of GLI2 (~78 kDa) and GLI3 (~83 kDa) were observed and 
significantly increased in expression across the TS patients when compared to the 
control individuals (Figure 9C). The expression was quantified and first internally 
normalized to the GAPDH expression per individual prior to comparing CT and TS 
expression overall (Figure 9D quantified via ImageJ software; For additional blots, see 
Supplementary Figure S3). The expression of GLI repressor proteins in controls are 
expectedly low, in line with typical human ventral telencephalic development. The 
increase in GLI repressor protein expression in TS is in line with the evident dorsal and 
posterior fate preference observed in organoids from these individuals.  
 
To explore this further, I revisited the TD14 RNA sequencing data, where the GO 
pathway analyses revealed that the top 10 downregulated categories were largely of a 
ciliary nature (Figure 9E). Given the significance of cilia in SHH signaling, and the 
potential alteration in downstream effectors of SHH signaling with upregulated GLI 
repressor protein expression in the TS organoids, the genes listed across all of the cilia-
related GO terms were pooled to create one single heatmap (Figure 9 Continued, F & 
G). These genes tend to be downregulated across the TS-derived basal ganglia 
organoids. While some of the genes are largely driven by two CT individuals, the 


















Taken together, these data suggest that cilia formation and development is altered in 
TS-derived basal ganglia organoids, with related SHH signaling alterations. The TS-
derived basal ganglia organoids show increased GLI Repressor protein expression for 
both proteins, GLI2 and GLI3, which are typically exclusive to a dorsal fate. In the 
presence of GLI Repressors, SHH signaling is inhibited, which can explain the 
mispatterning observed across all 5 of the TS individuals, where the derived basal 
ganglia organoids favor a dorsolateral and posterior neural development rather than the 
expected medioventral anterior neural development seen in the CT individuals. Further, 


Figure 9 Continued: Upregulation of GLI genes and disruption of cilia in TS-derived basal 
ganglia organoids. (F) Top 10 most significantly downregulated GO terms that meet significance 
(P < 0.05) at TD14. (G) Heatmap of the DGEs associated with the union of all ciliary GO terms 
from top 10 in panel A. All heatmaps show log2(1+rpkm) values were scaled in each row. For all 
TD14 RNA sequencing, N=5 TS; N=5 CT were submitted for analysis.  
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the ciliary disruptions observed are concentrated at TD14, suggesting the long term 
alterations of this critical cellular component. Finally, with their roles in cellular signaling, 
the ciliary disruptions – in both cilia development and SHH signaling capability – also 
support the observed trans-synaptic deficits seen across all three developmental time 



















Supplemental Figure S3: Additional GLI western blots. These western blots for GLI2 and GLI3 show 





This thesis offers a new bioassay to model basal ganglia development and provides the 
first investigation of TS in organoids. This work details a system for studying both 
normal and abnormal neurodevelopment. Utilizing iPSC technology, I generated basal 
ganglia organoids that show transcriptional programming distinct from cortical organoids 
(Chapter 4, Figure 1) [18]. The basal ganglia organoid protocol was then applied to 
examine TS. The recruited adult TS patients were diagnosed with persistent unremitting 
TS, with severe tic symptoms. Unremitting TS accounts for a subset of TS patients that 
correspond to approximately only 25% of TS diagnoses. Although TS is considered a 
heterogenous neurodevelopmental disorder with few linked mutations (See Chapters 1 
& 2), I identified neuronal deficits at both RNA and protein levels during an early 
developmental period that showed consistency across the five TS patients, as well as 
over three separate time points. Transcriptome analyses uncovered alterations in gene 
expression indicative of early telencephalic patterning disruptions that were seen across 
various stages of organoid development. Further, gene expression for proliferating 
progenitors and post-mitotic neuron types specific to the basal ganglia were reduced. 
Additionally, synaptic development appeared to be decreased in the TS-derived basal 
ganglia organoids, as well. 
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When examining transcriptome-based functional annotations, I found differences in 
early regional specification between the CT and TS-derived basal ganglia organoids. In 
contrast to the CT organoids, the TS-derived basal ganglia organoids favored dorsal-
posterior patterning, a phenotype observed at all three time points analyzed. These 
changes come from an apparent upregulation in both HOX and WNT signaling gene 
expression. The observed early preference for dorsal-posterior patterning – away from a 
ventral-anterior commitment – culminates in an enrichment for spinal cord development 
among upregulated DEGs in TS organoids at TD30. Importantly, these data are also 
consistent with the topographical shift observed by qPCR and RNA-sequencing,  
showing enhanced dorsal and LGE expression, and reduced MGE and POA expression 
in TS organoids. The deficit in ventral commitment is at least partially attributable to an 
early downregulation of SHH signaling genes seen by transcriptome analyses, and 
concordant loss of NKX2.1 expression seen at both RNA and protein levels.  
 
In addition to significant and consistent patterning alterations, I also found the 
expression of several neuronal subtypes to be downregulated in the TS-derived basal 
ganglia organoids. Most notably, deficiencies were seen across GABAergic, cholinergic 
and serotonergic genes. Expression of nitric-oxide (NOS) -related genes were also 
downregulated; NOS is a category of striatal interneurons, and this observed deficit in 
the organoid transcriptome reiterates findings from post mortem TS tissue [10]. Further, 
a broad but elaborate list of trans-synaptic signaling genes were also downregulated in 
the TS-derived basal ganglia organoids, indicating potential functional consequences in 
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these cultures. Previous transcriptome analyses of post mortem TS tissue show 
decreases in gene expression fitting GABAergic, cholinergic and serotonergic neuronal 
types. I found an interesting convergence of DEGs from the TS-derived organoids with 
the post mortem data. I did not expect to find a complete convergence of genes given 
the two distinct timepoints at the time of analysis – one representing early development 
while the other is adult post mortem. However, what can be appreciated from this data 
is the physiological relevance of the bioassay utilized for this study. Through this work, 
we see not only a portion of what is true in the human brain (and what is seen to be true 
for TS individuals) recapitulated in organoids, namely, decrease in markers for SST, 
NOS and cholinergic neurons, and a number of synaptic signaling related genes, but we 
also see an expansion of these findings to implicate early patterning genes that are 
instead not expressed in the adult brain. The two findings may be related to each other 
in the sense that the patterning defects may in part explain interneuron deficit—although 
further experiments are necessary to prove this point. In conclusion, the in vitro data are 
consistent with known roles for GABAergic, cholinergic and serotonergic genes in adult 
human TS, as well as insightful with the introduction of new biomarkers of interest. 
 
Given the patterning disruptions observed in the TS-derived organoids across time in 
conjunction with the deficits in the differentiation and maturation of particular cell types, I 
investigated a potential mechanism for the regional and cellular phenotypes. When 
examining critical components of SHH signaling transduction, two abnormalities were 
found: alterations in cilia development and function, as well as upregulation of GLI2 and 
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GLI3 repressor proteins in the TS-derived basal ganglia organoids. There is much to be 
considered with these findings, most notably the fact that ciliary disruptions are 
upstream of SHH signaling, while GLI production is a downstream component. While 
further investigation is required, I can offer postulates for the described data. The field 
details that, in the dorsal telencephalon, active PTCH inhibits the ability of SMO to 
accumulate in the cilium [362, 363]. Upon receptor binding, SHH inhibits PTC therefore 
allowing SMO cilia sequestration, which in turns triggers downstream components of the 
SHH pathway, including inhibition of PKA and GLI1 transcription (Chapter 6, Figure 9A). 
While SMO is not seen to be altered when comparing the CT and TS organoids at the 
RNA level, this does not confirm that SMO is ultimately appropriately sequestered to the 
cilium upon SHH treatment. Although it may be sufficiently transcribed, an insufficient 
sequestering of SMO receptor protein to the cilium in response to SHH in TS organoids 
could be a potential consequence of cilia malformation and malfunction. Continuing with 
this theory: a reduced concentration of SMO at the cilia may impair reaching a threshold 
of activation to ultimately induce GLI1 production and signaling, as my data also reveal 
early downregulation of GLI1 at the transcriptome level in TS organoids. Without 
sufficient cilia sequestration/activation of SMO, PKA phosphorylation of GLI2/3 proteins 
can still occur, flagging the GLI2/3 proteins for proteolytic lysing, as demonstrated by 
Western blot analyses in TS organoids. Post-translational modifications, such as 
phosphorylation, are known to be feedback regulators of cellular processes [364]. As 
such, PKA phosphorylation of GLI2 and GLI3 may initiate a positive feedback loop to 
engage further transcription of GLI2 and GLI3, which can explain the upregulation in 
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gene expression levels seen by qPCR further feeding the increased GLI repressor 
production for both GLI2 and GLI3 show in TS organoids. The field has a long history of 
evidence to show that GLI repressor activity inhibits ventral telencephalic development, 
and overexpression of GLI2 and GLI3 repressors lead to an expansion of dorsal 
commitment in ventral territory [315]. My data show a patterning shift in the TS-derived 
organoids away from a ventral-anterior commitment and toward a dorsal-posterior one, 
consistent with the field’s understanding of GLI repressor activity. Therefore, my data 
suggest an overall alteration in forebrain topography with an increase in dorsal-posterior 
patterning at the expense of ventro-anterior patterning (Figure 10A2, B2), (Figure 10A3, 
B3 respectively), in line with altered SHH signaling and increased GLI repressor 
generation. These data, in combination with these postulates, offer a potential 
developmental mechanism to explain the observed phenotype in the TS-derived basal 
ganglia organoids. For future investigation, protein studies can be performed to 
elucidate SMO protein production, appropriate transmembrane localization and activity. 
Additionally, PKA activity levels and phosphorylation can be investigated to determine 
intracellular processing of GLI proteins. 
 
The data presented here indicate new pathophysiological findings for TS and offer a 
new implication for SHH signaling. This work further reveals the suitability of a human in 
vitro tissue preparation for disease modeling, and offers a bioassay for investigation of 
other disorders affecting the basal ganglia. A potential mechanism for TS disorder 
pathogenesis is explored uncovering new significance for SHH signaling. Despite 
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disorder heterogeneity, these data illustrate the importance for a human model system 
that targets early development to explore and detect convergent pathophysiology. With 
new biomarkers identified, further investigation for therapies and advancement of 






















Figure 10: Schematic of cellular phenotype in organoids and prospective forebrain. Reading 
figure horizontally and from left to right – (A1) CT and (B1) TS subjects are biopsied, and their fibroblast 
cells are reprogrammed into iPSCs and differentiated into basal ganglia organoids (A2,B2). When 
assessing lineage topography across CT (A2) and TS (B2) organoids, the distribution of regions are 
disrupted in TS (B2). Based on these results: In contrast to the control brain (A3), the prospective 
forebrain for TS individuals may possibly show an expansion of dorsolateral expression and less of a 





Basal Ganglia Protocol 
 
DAY 0: 
1. Pre-treat cells with 5 uM ROCK inhibitor (Y-27632) in mTeSR for 45 minutes, to 
increase EB efficiency 
2. Wash media off cells with PBS, then add warmed Accutase (5 mL for each 10 cm 
dish) directly to cells (diluted 1:2 with PBS). Incubate at 37 degrees for about 10-
15 minutes 
3. Add 5 mL of mTeSR to dilute Accutase. Transfer the cells to a clean 50 ml tube. 
Add another 5 mL of PBS to gently wash off cells from dish 
4. Centrifuge cells at 1200 rpm for 4 min 
5. Aspirate supernatant and gently resuspend cells in 2 mL of neural EB medium 
growth factors free, without Vitamin A, but containing 5 uM Y-27632 
a. NB medium:  
i. DMEM-F12 with Glutamax base 
1% N2 
4% B27 (without Vitamin A) 
1% P/S 
55 uM BME 
6. Count cells in hemocytometer. Need 3 x 106 cells for each well of AggreWell 
a. Spin down again at 1200 rpm for 4 min 
b. Resuspend cells in 1.5 mL of NB medium supplemented with 5 uM Y-
27632 and 200ng/ml recombinant mouse Noggin 
c. Plate cells into AggreWell [See Rinsing Instructions for New AggreWells 
on TC desktop] 
i. Rinse each intended well with 1 mL of DMEM-F12 and aspirate to 
remove 
ii. Add 0.5 mL of NB complete medium (with Noggin & Y-27632) to 
each intended well 
iii. Centrifuge plate at 2000 x g for 5 minutes to remove air bubbles 
iv. Without removing the well’s media, add the 3 x 106 cells 
resuspended in 1.5 mL of NB complete medium and pipette gently 
up/down to distribute cells in well 
v. Centrifuge the AggreWell plate at 100 x g for 3 minutes and return 
cells to the incubator 
 
DAY 1: 





8. Collect EBs with a strainer* and move them to a 10 cm petri dish in 10 mL NB 
medium (from now on the NB medium uses REGULAR B27) + 5 uM Y-27632 
and 200 ng/mL Noggin. Disperse by shaking the plate before putting in incubator. 
1 well = 1 10 cm dish 
a. Strainer: collect EBs using 2 mL pipette over an inverted 40 uM-cell 
strainer on top of a 50 mL falcon tube and wash well 2-3 times with 2 mL 
DMEM-F12 to obtain more EBs from well. The EBs should be collected on 
the bottom side of the strainer. Then put the cell strainer right side up on 
the petri dish and spray the EBs with 10 mL NB medium + 5 uM Y-27632 
and 200 ng/mL Noggin.] 
 
DAY 3: SKIP THIS DAY 
 
DAY 4: 
9. Transfer the EBs to a 15 mL conical tube and let the EBs settle by gravity. 
Replate EBs using NB medium + 200 ng/mL of Noggin (no more Y-27632) on 
Tissue Grade plates coated with 2x growth factor-reduced Matrigel. Neural EBs 
should attach and spread out the next day. 
 
DAY 5: 
10.Change medium and supplement with 20 ng/mL FGF2, 200 ng/mL Noggin and 
200 ng/mL rhDKK1. Over the next few days, rosettes should appear. Change 
media every other day. May take up to 3 days to appear. 
 
~DAY 7: 
11.Harvest rosettes by extracting central area of each spreading EB using a pipette 
tip and the dissectorscope. Successful plates should have ~90-95% of EBs 
turned into rosettes. Collect all of them and replate the rosettes in suspension in 
bacterial grade petri dishes for 4 full days. Plate in NB medium + FGF2 & EGF 














DAY 12:  
Terminal Differentiation Day 0 
12.Manually place individual organoids in 1 well of 96 well plate using large orifice 
pipette tips and dissector scope 
Replenish well media with TD medium + ventral morphogens
a. TD medium: most preps will need volumes of 100 mL 





1% DMEM-F12 + Glutamax 
1% NEAA 
55 uM BME 
 
b. Add growth factors FRESH to whatever volume of TD medium is 




500x Ascorbic Acid 
200x cAMP 
 
c. AND Add ventral morphogens FRESH to whatever volume of TD 
medium is necessary to replenish the media on that day. 
100 ng/mL FGF8 
1 uM SHH 
500 ng/mL (light sensitive) RA 
10 ng/mL BMP9 
 
14.Change media 2x/week (I change media on Tuesdays and Fridays) 
** I only expose the organoids to the ventral morphogens for 7 days. This allows 
for 2 media changes with fresh ventral morphogens before changing the TD 
media to only having growth factors. Even still, I never remove the media fully. 
When the media is added to the 96 wells on TD0, I add 200 ul of TD media. 
Every time I refresh the media, I remove and discard 150 ul of old media from the 
well and add a fresh 150 ul to the well. After 7 days, the remaining ventral 
morphogen solution in the well will continue to be naturally titrated out with each 
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